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ABSTRACT OF THE DISSERTATION 
Understanding the Molecular Pathogenesis of Retinal Neurodegeneration 
by 
Jonathan Beaux Lin 
Doctor of Philosophy in Biology and Biomedical Sciences 
Neurosciences 
Washington University in St. Louis, 2020 
Professor Rajendra Apte, Chair 
Retinal degenerative diseases are a major cause of morbidity in modern society because visual 
impairment significantly decreases the quality of life of patients. A significant challenge in 
treating retinal degenerative diseases is their genetic and phenotypic heterogeneity. Furthermore, 
limitations in our understanding of disease pathophysiology have led to reliance on therapies that 
often treat disease endpoints rather than addressing disease etiology and/or pathophysiology. The 
long-term goal of my thesis research was to provide molecular and cellular insights into the 
pathophysiology underlying diverse retinal degenerative diseases, which may lead to much-
needed, novel therapeutic approaches. During the first part of my thesis research, I discovered 
that impaired NAD+ homeostasis is a central feature of diverse retinal degenerative diseases 
(Chapter 2). For the second part of my thesis research, I found that the central cellular phenotype 
of aged macrophages, which are known to promote age-related macular degeneration, is 
impaired cholesterol homeostasis (Chapter 3) and that the transition towards this disease-
promoting, aged phenotype is regulated, in part, by microRNA-150 (Chapter 4). Although 
further research is necessary to translate these findings to the bedside, they have the potential to 
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Vision is a central sense that is considered critical in modern society. Numerous studies 
have demonstrated that visual impairment is associated with significant morbidity and has a huge 
impact on one’s quality of life. For example, visual impairment is associated with clinically 
significant decreases in mobility and independence (Fenwick et al., 2016). Furthermore, in 
patients with the blinding disease retinitis pigmentosa (RP), there is a correlation between 
residual visual field and quality of life (Chaumet-Riffaud et al., 2017), suggesting that there is an 
association between the degree of vision loss and the extent of impairment in quality of life. 
These decreases in quality of life can contribute to poor mental health. In support, Heesterbeek 
and colleagues found that a prospective cohort of 540 older adults with vision impairment 
exhibited twice the incidence of subthreshold depression and anxiety compared to older adults in 
general (Heesterbeek et al., 2017). Although these symptoms tended to fluctuate with time, 
having macular degeneration and problems with adapting to vision loss were two of the risk 
factors identified for developing depressive symptoms (Heesterbeek et al., 2017). Therefore, 
vision loss and the associated sequelae have a significant impact on human beings individually 
and on society in general. As such, despite their challenges, preventing and reversing vision loss 
caused by diverse retinal diseases are of utmost priority. 
 Retinal degenerative diseases make up a significant portion of the burden of blindness 
and are often untreatable. The retina is a complex, light-sensitive, neurovascular tissue with a 
highly organized structure that is essential to its function (Figure 1.1). Located at the posterior 
pole of each eye, the retina consists of numerous cell types, all of which must function in a 
coordinated manner to generate a neural signal to be transmitted to the occipital lobe of the brain 




before being sensed by the photoreceptors on the posterior aspect of the retina. Photoreceptors 
can be divided into two types:  rod photoreceptors mediate dim, peripheral vision, whereas cone 
photoreceptors mediate central, color vision. The signal from the photoreceptors is then 
transmitted to secondary neurons known as bipolar cells before being transmitted to the retinal 
ganglion cells, whose axons coalesce to form the optic nerve. Horizontal and amacrine cells 
provide lateral modulation. As expected, conditions leading to the death of any of these 
subpopulations of retinal neurons can lead to visual impairment. In particular, photoreceptor 
death is a common cause of blindness in retinal degenerative diseases, as these light-sensitive 
neurons are responsible for the initial transduction of light. 
 In this chapter, I will first provide a brief clinical description of various examples of 
retinal degenerative diseases to frame a discussion regarding the limitations of their current 
treatment options. Chapters 2, 3, and 4 describe three distinct research projects that I have 
undertaken during my graduate training with the long-term goal of improving our understanding 
of the pathophysiology underlying retinal degenerative diseases. Although further research is 
necessary to more fully understand the molecular and cellular pathways involved in these 
processes and, ultimately, to translate these findings from the bench to the bedside, these 
therapies have the potential to be highly innovative and may transform the care that clinicians 
can offer to patients with retinal degenerative diseases. 
 
1.2 Retinal Degenerative Diseases 
Retinal degenerative diseases are a heterogeneous family of multiple conditions all 
involving death or damage to cells of the retina. These diseases have a wide array of etiologies: 




Although some of these conditions share phenotypic characteristics, most have different 
underlying pathogeneses. This diversity makes it rather challenging to develop unifying 
therapeutic strategies. Instead, the prevailing dogma has been to consider each disease as a 
separate entity with its own avenue of research, discovery, and translational pipeline. 
 
1.3 Age-Related Macular Degeneration 
Age-related macular degeneration (AMD) is an acquired retinal degenerative disease that 
affects the central retina, called the macula. AMD is a leading cause of blindness in adults over 
the age of 50 years. AMD is projected to become an even larger problem over time and is 
predicted to affect as many as 288 million people by 2040 (Wong et al., 2014). Clinically, 
patients with early-stage AMD often complain about reduced light sensitivity, dark adaptation, 
and contrast sensitivity, which is believed to be related to early parafoveal rod photoreceptor 
degeneration (Curcio et al., 1996). On examination, these patients often present with the 
presence of lipid- and protein-rich deposits known as drusen in the sub-retinal space. Drusen 
themselves do not usually cause vision loss, but they are a significant risk factor for progression 
to advanced AMD that manifests either as advanced non-neovascular (dry) AMD or neovascular 
(wet) AMD. Both forms of advanced disease can lead to significant visual impairment related to 
secondary degeneration and death of macular photoreceptors, causing loss of central vision. In 
the case of advanced dry AMD, blindness is caused by death of the photoreceptors due to loss of 
the underlying retinal pigment epithelium (RPE) cells that are critical for photoreceptor survival 
and function. This stage of disease is called geographic atrophy (GA). In contrast, in wet AMD, 
pathological angiogenesis manifests as choroidal neovascularization (CNV), which can also 




difficult for clinicians to counsel AMD patients regarding when progression to advanced disease 
may occur and what form it will take. The Age-Related Eye Disease Study (AREDS), sponsored 
by the National Eye Institute, was a large cohort study that provided key insights into the natural 
history of AMD. This study also identified risk factors associated with progression from early or 
intermediate AMD to advanced AMD, such as smoking and greater body mass index (BMI) 
(Clemons et al., 2005). Nonetheless, further research is necessary to determine the specific 
molecular and cellular mechanisms that underlie AMD pathogenesis. 
Genome-wide association studies have provided some clues into potential pathogenic 
mechanisms underlying AMD by identifying that polymorphisms in complement factor H, 
hepatic lipase (LIPC), ATP-binding cassette transporter member 1 (ABCA1), and cholesterol 
ester transfer protein (CETP), are associated with early or advanced AMD (Hageman et al., 
2005; Neale et al., 2010). These findings implicate altered regulation of inflammation and 
aberrant lipid homeostasis as potential contributors to the pathogenesis of AMD. In support, 
mouse models designed to mimic perturbations in inflammation or lipid homeostasis pathways in 
combination with environmental factors, such as a high-fat, Western diet, have been reported to 
recapitulate some features resembling AMD (Malek et al., 2005; Sene et al., 2013; Toomey et 
al., 2015). These findings confirm the relevance of these pathways in AMD and highlight the 
value of using mouse models for furthering our understanding of AMD. 
Currently, approved therapies for wet AMD include drugs directed against vascular 
endothelial growth factor (VEGF). VEGF is a key driver of pathological angiogenesis, the 
hallmark of wet AMD. Although anti-VEGF therapies have revolutionized treatment for wet 
AMD, long-term studies have demonstrated that atrophic neurodegeneration with loss of 




more importantly, some patients do not respond or are under-responsive to this therapy (Inoue et 
al., 2016; Kim et al., 2016; Sarwar et al., 2016; Sene et al., 2015), suggesting that VEGF-
independent pathways may also contribute to AMD pathogenesis. More research is needed to 
identify alternate therapeutic strategies that may be able to provide clinical benefit for these 
patients and to prevent photoreceptor neurodegeneration in both forms of advanced AMD. 
Unfortunately, because the pathophysiology of dry AMD remains incompletely understood, there 
are currently no approved therapies for dry AMD. High-dose supplementation of vitamins C and 
E, beta carotene, and zinc has been suggested to modestly slow progression to advanced AMD 
(Age-Related Eye Disease Study Research, 2001), but the effect size is fairly small, and its 
mechanism is still unclear. Taken together, it is clear that there is a paucity of current treatment 
options for AMD patients beyond targeting VEGF in wet AMD. 
 
1.4 Diabetic Retinopathy 
Diabetes mellitus is a systemic metabolic disease characterized by deficits in blood 
glucose control. The pathophysiology of diabetes mellitus is complex and affects numerous 
organ systems, but one component of this systemic disease is diabetic retinopathy (DR). 
Clinically, DR consists of early microvascular damage, which is initially characterized by 
pericyte loss and microaneurysms in small-caliber vessels in the retina, followed by capillary 
wall damage, leakage, exudation, and retinal edema. In advanced disease, hypoxic pathologic 
neovascularization can cause vision loss secondary to hemorrhage and detachment of the 
neurosensory retina. In addition to this vascular phenotype, diabetic patients often exhibit 
changes detectable with electroretinography (ERG), such as delayed implicit times (Satoh et al., 




changes. DR could therefore include two components – neuroretinal dysfunction and vascular 
dysfunction – with both contributing to vision loss. 
Studies in mouse models of DR support this possibility. For example, Rajagopal and 
colleagues identified that mice weaned to high-fat chow exhibit modest electrophysiological 
dysfunction in the form of increased latencies and decreased oscillatory potential amplitudes at 
six months that precede the vascular phenotype of microvascular disease that can be observed by 
12 months (Rajagopal et al., 2016). These findings may have translational relevance since 
multifocal ERG implicit times in patients with diabetes but without retinopathy predict future 
development of DR (Harrison et al., 2011). Other groups have reported even more striking high-
fat diet-induced retinal dysfunction in mice at 12 weeks in the form of reduced scotopic and 
photopic ERG amplitudes (Chang et al., 2015). Mechanistic studies suggest that this neuroretinal 
dysfunction may be due to the sensitivity of retinal neurons to systemic hyperglycemia. For 
example, in the streptozotocin-induced mouse model of diabetes, prolonged hyperglycemia leads 
to retinal oxidative stress (Du et al., 2013), which may contribute to photoreceptor death. 
Currently, clinicians can treat only the vascular disease, including permeability-related 
macular edema and ischemic neovascularization, with anti-VEGF pharmacotherapy and 
intraocular steroids. Neuroprotective strategies that could mitigate neuroretinal dysfunction or 
prevent retinal neurodegeneration are highly attractive but are currently investigational. As in 
AMD, a molecular understanding of the pathophysiology of DR might improve our ability to 







1.5 Inherited Retinal Degenerations 
Inherited retinal degenerations (IRDs) are diverse diseases that are associated with 
progressive vision loss caused by mutations in over 250 genes. Some examples of IRDs include 
RP, Leber congenital amaurosis (LCA), and rod-cone or cone-rod dystrophies. IRDs can be 
isolated or syndromic. For example, RP, one of the most common IRDs, can be caused by 
mutations in any of more than 100 genes or can be a clinical feature of Usher syndrome or 
Bardet-Biedl syndrome. Because of this genotypic diversity, RP has a complex and 
heterogeneous clinical presentation that often depends on the underlying mutation. In general, 
RP patients present with loss of night vision and decreased peripheral vision due to death of rod 
photoreceptors. As rod photoreceptor death progresses, cone photoreceptor death may follow as 
a secondary effect of losing rod photoreceptor-derived survival factors. Exome and targeted gene 
sequencing have made it possible to examine the genetic etiology of various retinal degenerative 
diseases, including RP. 
Despite remarkable advances in our ability to identify the causative gene mutations 
associated with IRDs, including RP, our therapeutic strategies are still limited by lack of 
knowledge of the mechanisms by which these gene mutations cause disease. One therapeutic 
approach has been gene therapy with the goal of replacing the defective copy or copies of the 
affected gene with a normal gene delivered by a carrier, usually a viral vector. For example, a 
Phase III trial recently evaluated the safety and efficacy of voretigene neparvovec (AAV2-
hRPE65v2) in patients with retinal dystrophy caused by biallelic mutations in RPE65 (Russell et 
al., 2017). Using this approach, a wild-type copy of the RPE65 gene is delivered with an 
adenoviral vector to the sub-retinal space. In patients with viable retinal cells, normal RPE65 




its infancy compared to conventional gene therapy, CRISPR-Cas9 has also now made it possible 
to perform targeted gene editing to repair disease-causing mutations, which has been shown to be 
effective in restoring some vision in rodent models of retinal degenerative disease (Bakondi et 
al., 2016; Wu et al., 2016). However, one major challenge of both gene therapy and gene editing 
is that they would have to be optimized and targeted for each specific mutation, requiring the 
causative mutation to be identified in each individual patient. This requirement is a challenging 
proposition considering the diversity of mutations that have been identified, especially for RP, 
each affecting a fraction of the total patient population. Perhaps of additional concern, gene 
therapy is incredibly expensive in the present, making it difficult to use in widespread settings. 
Issues surrounding the durability of the effect, effect size, and scalability in more prevalent 
diseases further complicate the therapeutic landscape. 
 
1.6 Limitations of Current Therapeutic Approaches 
For many retinal degenerative diseases, our incomplete understanding of disease 
pathogenesis has led to a current strategy of addressing disease symptoms and endpoints rather 
than their underlying etiology. For example, in AMD and DR, patients receive anti-VEGF 
therapies to inhibit pathological angiogenesis. For IRDs, even if we have a sophisticated 
understanding of the underlying genetics, it is not always easy to deliver therapeutics in a clinical 
setting due to the challenges highlighted above. Therefore, an attractive option would be to 
identify a potential therapeutic strategy that could prevent photoreceptor death in multiple forms 
of retinal degenerative diseases. One example of such an approach is stem cell therapy. Previous 
mouse studies have shown that photoreceptor neuron transplantation is feasible and improves 




investigations have been the basis of ongoing human clinical trials using stem-cell based 
approaches in AMD (Mandai et al., 2017; Schwartz et al., 2015; Schwartz et al., 2016). Although 
these studies adopt the strategy of RPE transplantation rather than photoreceptor neuron 
transplantation since RPE dysfunction is known to contribute to photoreceptor degeneration in 
advanced dry AMD, they demonstrate that transplantation of cells into the eye is feasible, paving 
the way for future human clinical studies of photoreceptor transplantation. 
There remain numerous challenges of using stem cells for photoreceptor transplantation, 
such as ensuring proper functional connectivity with the host retina, the time required to 
differentiate cells for transplantation, and potential tumorigenicity of transplanted cells. Recent 
studies also suggest that material transfer of proteins from transplanted photoreceptors to host 
cells may itself improve visual function, necessitating a closer look at the mechanism underlying 
rescue in transplantation studies (Pearson et al., 2016; Waldron et al., 2018).These are important 
issues that must be investigated thoroughly before stem cell therapy can be widely used in 
humans. The source of stem cells also poses a significant challenge. Although induced 
pluripotent stem cells (iPSCs) can be used to overcome the ethical concerns and regulatory 
challenges surrounding embryonic stem cells since iPSCs are reprogrammed from adult somatic 
cells, they have one major limitation: specifically, since the source of iPSCs is often the patients 
themselves, the cells retain disease-causing mutations, requiring gene editing prior to 
transplantation. Although targeted gene editing can be achieved with CRISPR-Cas9 in mouse 
models (Burnight et al., 2017), successful application of this technology to treat retinal 







Retinal degenerative diseases are a major cause of morbidity in the modern world. Visual 
impairment significantly diminishes the quality of life of patients. A significant challenge in 
preventing blindness caused by retinal diseases is the genetic and phenotypic heterogeneity of 
the diseases and a variable understanding of disease pathogenesis. This limited understanding 
has led to either the widespread use of drugs that treat disease manifestations in relatively late 
phases of the natural history rather than the underlying cause or, in many instances, a complete 
lack of treatment options altogether. Indeed, more research is necessary to identify novel 
therapeutics for early and targeted intervention. Some strategies, such as gene therapy and stem 
cell-based therapeutic approaches, have been proposed, although they have limitations, such as 
the fact that gene therapy would have to be tailored for the causative mutation of each individual 
disease. The ability to identify novel therapies for diverse retinal diseases is highly attractive and 







Figure 1.1. Schematic depicting the structural organization of the neurosensory retina and its location in the eye. 
The retina consists of numerous neuronal cell types, including rod and cone photoreceptors, bipolar cells, retinal 
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Photoreceptor death is the endpoint of many blinding diseases. Identifying unifying 
pathogenic mechanisms in these diseases may offer global approaches for facilitating 
photoreceptor survival. We found that rod or cone photoreceptor-specific deletion of 
nicotinamide phosphoribosyltransferase (Nampt), the rate-limiting enzyme in the major NAD+ 
biosynthetic pathway beginning with nicotinamide, caused retinal degeneration. In both cases, 
we could rescue vision with nicotinamide mononucleotide (NMN). Significantly, retinal NAD+ 
deficiency was an early feature of multiple mouse models of retinal dysfunction, including light-
induced degeneration, streptozotocin-induced diabetic retinopathy, and age-associated 
dysfunction. Mechanistically, NAD+ deficiency caused metabolic dysfunction and consequent 
photoreceptor death. We further demonstrate that the NAD+-dependent mitochondrial deacylases 
SIRT3 and SIRT5 play important roles in retinal homeostasis and that NAD+ deficiency causes 
SIRT3 dysfunction. These findings demonstrate that NAD+ biosynthesis is essential for vision, 
provide a foundation for future work to further clarify the mechanisms involved, and identify a 






Vision is a crucial sense that depends on photoreceptors for light transduction. 
Photoreceptors are divided into two classes: rods and cones. Rod photoreceptors mediate dim 
vision, while cone photoreceptors mediate precise central vision in ambient light. Photoreceptors 
make up a significant portion of the neurosensory retina, one of the most metabolically active 
tissues in the body (Ames et al., 1992; Kooragayala et al., 2015; Okawa et al., 2008). Although 
terminally differentiated and non-proliferative, photoreceptors have tremendous metabolic 
demands throughout their lives and experience significant light-induced oxidative stress due to 
their function of performing light transduction (Fu and Yau, 2007; Yau and Hardie, 2009). 
Because of the critical role that photoreceptors play in light transduction, photoreceptor 
death leads to blindness. Despite their differing etiologies, many blinding diseases share this 
final pathway of photoreceptor death, which inevitably causes vision loss. For example, age-
related macular degeneration (AMD) is one leading cause of blindness in older adults (Apte, 
2010; Klein et al., 2004; van Leeuwen et al., 2003). Although advanced AMD takes on two 
forms (i.e., dry or wet AMD) (Sene and Apte, 2014), both pathways ultimately lead to 
photoreceptor death. Similarly, inherited retinal degenerations, including retinitis pigmentosa 
(RP), rod and cone dystrophies, and Leber congenital amaurosis (LCA), are caused by genetic 
defects in over 100 different genes that lead to photoreceptor death (Astuti et al., 2015; Hartong 
et al., 2006; Wright et al., 2010). Developing treatment strategies for this broad spectrum of 
retinal degenerative diseases is challenging given these diverse pathogenic mechanisms. 
Nicotinamide adenine dinucleotide (NAD+) is both an essential coenzyme, functioning as 
an electron carrier in glycolysis and the Krebs cycle, and an essential cosubstrate for NAD+-




ribosyltransferases, and cyclic ADP-ribose hydrolase (CD38) (Ying, 2006). Given these 
numerous functions, NAD+ has been shown to be important in many biological processes, 
including metabolism (Garten et al., 2009; Mouchiroud et al., 2013), circadian rhythms 
(Nakahata et al., 2009; Ramsey et al., 2009), and aging (Imai and Guarente, 2014). Relevant to 
our studies, NAD+ has also been shown to be important in neurodegeneration (Alano et al., 2010; 
Gerdts et al., 2015; Stein et al., 2014; Zhou et al., 2015). However, the role of NAD+ in retinal 
degeneration has been relatively unexplored to date. 
We hypothesized that NAD+ biosynthesis plays an important role in photoreceptor 
function and survival. This hypothesis is supported by past studies demonstrating that LCA, the 
leading cause of childhood blindness from retinal disease, can be caused by mutations in 
nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1) (Chiang et al., 2012; Falk et al., 
2012; Koenekoop et al., 2012; Perrault et al., 2012), an enzyme involved in NAD+ biosynthesis. 
The various mutant forms of NMNAT1 associated with LCA exhibit reduced NAD+ biosynthetic 
capacity and/or impaired protein folding (Falk et al., 2012; Koenekoop et al., 2012; Sasaki et al., 
2015) with both factors contributing to disease pathogenesis. 
NAD+ can be synthesized in three ways: 1) de novo from tryptophan, 2) salvaged from 
nicotinamide or nicotinic acid (NAM or NA, respectively), or 3) from nicotinamide riboside 
(NR). In mammals, the salvage pathway beginning with NAM is the predominant NAD+ 
biosynthetic pathway (Imai and Yoshino, 2013; Imai and Guarente, 2014). The first step of this 
pathway is catalyzed by nicotinamide phosphoribosyltransferase (NAMPT), which combines 
NAM with 5-phosphoribosyl pyrophosphate (PRPP) to form nicotinamide mononucleotide 




In this study, we focus on the role of NAMPT-mediated NAD+ biosynthesis in 
photoreceptor survival and vision. Our results suggest that NAD+ biosynthesis may be important 
not only in LCA but also in a broad spectrum of retinal degenerations and age-associated retinal 
dysfunction. Thus, it may be possible to use NAD+ intermediates to protect against retinal 
degeneration. Although these findings provide a strong foundation for future studies, further 
work is needed to clarify the mechanisms involved. If successful, this therapeutic strategy would 




Loss of NAMPT-mediated NAD+ biosynthesis impairs photoreceptor survival and vision 
Photoreceptors are one of the most metabolically active cells of the body with demanding 
energy requirements (Ames et al., 1992; Okawa et al., 2008) but limited mitochondrial reserve 
capacity (Kooragayala et al., 2015). Therefore, we hypothesized that photoreceptors depend on 
NAMPT-mediated NAD+ biosynthesis to meet their catalytic requirements. To test this 
hypothesis, we examined the effect of disrupting NAMPT-mediated NAD+ biosynthesis 
selectively in rod photoreceptors by generating conditional knockout mice lacking Nampt 
(Nampt-rod/-rod). 
As expected, rod-enriched retinal isolates from Nampt-rod/-rod mice showed significant 
reduction in Nampt gene expression (Figure 2.1A). This rod photoreceptor-specific deletion of 
Nampt led to a ~26% reduction in retinal NAD+ levels in Nampt-rod/-rod mice compared to 
NamptF/F littermates at 3 weeks (Figure 2.1B). We also measured NAD+ levels in rod-enriched 




photoreceptors. We found that rod-enriched isolates from Nampt-rod/-rod mice had a ~43% 
reduction in NAD+ levels compared to those from NamptF/F mice (Figure 2.1C), suggesting that 
the NAD+ deficiency is predominantly specific to the rod photoreceptors. 
On biomicroscopy, we found that Nampt-rod/-rod mice had a degenerative phenotype that, 
by 6 weeks, was characterized by massive atrophy of the neurosensory retina, vascular 
attenuation with pigment mottling, and atrophy of the underlying retinal pigment epithelium 
(RPE) cells, which was not observed in NamptF/F littermates (Figure 2.1D). This neurosensory 
retinal degeneration was also associated with secondary atrophy and pallor of the optic nerve 
(Figure 2.1D). We confirmed this degeneration with histological examination of eyes from 
Nampt-rod/-rod mice. Although the histology was relatively normal at 2 weeks (data not shown), 
there was progressive loss of the outer nuclear layer with associated retinal degeneration, 
significant reduction of retinal thickness, and secondary extension to multiple retinal layers in 
Nampt-rod/-rod eyes that was complete by 6 weeks (Figure 2.1E). Of note, the outer nuclear layer 
(arrows; Figure 2.1E) appeared to be almost completely absent by 6 weeks, indicating 
substantial photoreceptor death. 
We performed electroretinography (ERG) to confirm the functional deficits associated 
with this profound anatomic degeneration. By 6 weeks, Nampt-rod/-rod mice demonstrated a 
dramatic reduction in the amplitudes of rod-generated scotopic a-waves (Figure 2.1F), 
indicating significant impairment of rod function. This impairment in rod photoreceptor function 
also led to declines in the amplitudes of the scotopic b-waves (Figure 2.1G). Interestingly, 
Nampt-rod/-rod mice also exhibited deficits in cone function, as manifested by a decline in the 
amplitudes of the photopic b-waves (Figure 2.1H). Although Nampt deletion was specifically in 




observed as a secondary effect of rod photoreceptor degeneration since rods are required for cone 
survival (Ait-Ali et al., 2015; Wong and Kwok, 2016). Consistently, by 6 weeks, Nampt-rod/-rod 
mice had significantly worse photopic visual acuity compared to age-matched NamptF/F controls 
(Figure 2.1I). As such, our findings replicate the progression of rod degeneration followed by 
cone degeneration often observed in patients with inherited retinal degenerations such as RP. 
We also generated Nampt-rod/wt mice to determine the effect of partial ablation of 
NAMPT-mediated NAD+ biosynthesis. As expected, rod-enriched retinal isolates from Nampt-
rod/wt mice exhibited partial reduction in Nampt expression compared to NamptF/wt controls (data 
not shown), which was roughly half of the reduction in Nampt-rod/-rod versus NamptF/F mice. This 
monoallelic Nampt deletion did not cause a statistically significant reduction in retinal NAD+ 
levels nor did it cause significant retinal degeneration by 6 weeks as measured by ERG (data not 
shown), suggesting that Nampt is haplosufficient during this short time scale. 
To confirm that the effect of Nampt deletion was cell autonomous, we generated mice 
lacking Nampt specifically from cone photoreceptors (Nampt-cone/-cone). Although cones constitute 
only ~3% of photoreceptors, they are exclusively responsible for precise color and central vision 
in humans. As expected, immunohistochemistry revealed reduced intracellular NAMPT staining 
(red) within cone photoreceptors (green) in retinal sections from Nampt-cone/-cone mice, while 
retinal sections from NamptF/F mice demonstrated robust cone NAMPT expression (Figure 
2.2A). 
Biomicroscopic imaging of Nampt-cone/-cone mice demonstrated changes consistent with 
cone degeneration, including mottling of the RPE and pallor of the optic nerve (Figure 2.2B). 
This structural degeneration also manifested in functional deficits by ERG.  By 6 weeks, Nampt-




and 2.2D). More strikingly, Nampt-cone/-cone mice exhibited dramatic declines in the amplitudes of 
their photopic b-waves (Figure 2.2E), indicating predominant cone dysfunction. These structural 
and functional changes in Nampt-cone/-cone mice were also associated with a significant decrease in 
photopic visual acuity (Figure 2.2F). Cumulatively, these findings provide strong support for the 
essential role of NAMPT-mediated NAD+ biosynthesis in photoreceptor survival, as cell-specific 
deletion of this key enzyme led to rapid photoreceptor degeneration and vision loss. 
 
Exogenous NMN prevents photoreceptor degeneration and restores vision 
 To confirm the importance of NAMPT-mediated biosynthesis in photoreceptor survival, 
we tested whether exogenous supplementation with NMN could rescue photoreceptor 
degeneration by bypassing the NAMPT-catalyzed reaction. NAMPT catalyzes the conversion of 
NAM to NMN and should reduce photoreceptor death by ameliorating the NAD+ deficiency. We 
gave Nampt-rod/-rod mice daily intraperitoneal injections of NMN (150 mg/kg) or vehicle alone 
beginning at P5 and ending at the time of ERG testing. Strikingly, ERG at 4 weeks in NMN-
treated Nampt-rod/-rod mice revealed significant recovery of scotopic and photopic retinal function 
compared to vehicle-treated Nampt-rod/-rod mice (Figures 2.3A, 2.3B, and 2.3C). There was no 
dramatic effect of NMN on the ERG of NamptF/F controls (data not shown). Consistently, retinal 
sections from NMN-treated Nampt-rod/-rod mice showed rescue of retinal degeneration compared 
to vehicle-treated Nampt-rod/-rod mice, as manifested by relative preservation of the outer nuclear 
layer (Figure 2.3D). 
Correspondingly, daily intraperitoneal NMN injections also significantly improved 
retinal function by ERG in Nampt-cone/-cone mice compared to vehicle-treated Nampt-cone/-cone mice 




biosynthesis is necessary for the survival and function of both rod and cone photoreceptors, as 
promoting NAD+ biosynthesis in the retina with NMN supplementation can compensate for 
Nampt deletion, thereby reducing photoreceptor death and improving vision. 
 
Early NAD+ deficiency is a feature of multiple mouse models of retinal dysfunction 
 Next, we sought to determine whether NAD+ deficiency is an early feature of other 
mouse models of retinal disease or dysfunction, which would support the possibility that NAD+ 
intermediates may have therapeutic potential against a broad spectrum of retinal degenerative 
diseases. Light-induced degeneration is a well-characterized model that is widely used to study 
mechanisms of photoreceptor death (Grimm and Reme, 2013) and is known to cause retinal 
dysfunction, which can be observed by histology and ERG (Schimel et al., 2011). We found that 
there was a significant reduction in retinal NAD+ levels as early as 24 hours following light 
exposure (Figure 2.3H). In addition, we tested whether mice with streptozotocin (STZ)-induced 
diabetic retinopathy, whose retinal dysfunction has been well characterized (Samuels et al., 
2015), exhibit retinal NAD+ deficiency. At 3 weeks after STZ induction, hyperglycemic mice 
had a significant reduction in retinal NAD+ compared to non-hyperglycemic controls (Figure 
2.3I). Finally, it is well known that there are defects in retinal structure and function in old mice, 
such as a decreased number of rod photoreceptors, a decreased level of total opsin in the retina, 
and diminished rod ERG recordings (Kolesnikov et al., 2010; Lin et al., 2016b). Consistent with 
these past reports, we found that 18-month-old wild-type mice (C57BL/6J) had worse retinal 
function on ERG compared to strain-matched 6-month-old mice from the same source (data not 
shown). As in light-induced degeneration and STZ-induced diabetic retinopathy, this age-




(Figure 2.3J). These findings support the idea that NAD+ deficiency may be a shared feature of 
retinal dysfunction. 
 
NMN rescues retinal dysfunction in light-induced degeneration 
 Since we showed that there is NAD+ deficiency associated with the retinal dysfunction 
that follows light-induced degeneration, we sought to determine whether exogenous NMN 
supplementation to rescue NAD+ deficiency would rescue retinal dysfunction. We gave wild-
type mice (129S1/SvImJ) daily intraperitoneal injections of NMN (300 mg/kg) or vehicle alone 
beginning 6 days prior to light exposure, on the day of light exposure, and for 3 days following 
light exposure (total of 10 injections/mouse). Remarkably, NMN-treated wild-type mice were 
more resilient against light exposure and retained improved retinal function as measured by ERG 
compared to vehicle-treated mice (Figures 2.4A, 2.4B, and 2.4C). These findings suggest that 
the NAD+ deficiency associated with retinal disease can indeed be rescued by NAD+ 
intermediates such as NMN, further supporting the possibility of using NAD+ intermediates to 
treat retinal degenerative diseases. 
 
Loss of NAMPT-mediated NAD+ biosynthesis leads to metabolic dysfunction 
To provide insight into how NAD+ deficiency leads to retinal degeneration, we 
performed transmission electron microscopy on Nampt-rod/-rod retinas. Although there were no 
obvious differences in mitochondrial ultrastructure at 3 weeks, we observed profoundly 
dysmorphic changes in photoreceptor inner segments by 4 weeks along with disruption of the 
outer segments, which we did not observe in NamptF/F littermates of the same age (data not 




constricted with loss of cristae and a morphology that was distinctly different from that observed 
in NamptF/F littermates (Figure 2.4D). In addition, at this time point, we observed degenerative 
vacuoles in the cytoplasm of Nampt-rod/-rod retinas, which appeared to contain degenerated 
organelles including ruptured mitochondria (data not shown). These results suggest that loss of 
NAMPT-mediated NAD+ biosynthesis in photoreceptors leads to mitochondrial structural 
irregularities that may lead to or be associated with defects in mitochondrial function. 
To characterize these possible mitochondrial defects, we performed non-biased 
metabolomic analysis with liquid chromatography-mass spectrometry (LC-MS) and gas 
chromatography-mass spectrometry (GC-MS), comparing retinas isolated from 3-week old 
Nampt-rod/-rod mice to those isolated from gender-matched NamptF/F littermates. We chose this 
time point since it would allow us to identify signs of mitochondrial dysfunction that precede 
gross retinal degeneration. The LC-MS results revealed that although there were no statistically 
significant differences, there was a trend toward accumulation of some acylcarnitine species in 
Nampt-rod/-rod retinas, suggesting a possible defect in Krebs cycle efficiency (data not shown). In 
addition, the GC-MS results revealed that numerous mitochondrial metabolites were 
significantly elevated or reduced in Nampt-rod/-rod retinas. To determine whether the identities of 
these dysregulated metabolites were suggestive of defects in certain metabolic pathways, we 
performed metabolite set enrichment analysis with MetaboAnalyst 3.0 (Xia et al., 2015) using 
the over representation analysis algorithm. This analysis revealed that there are numerous 
metabolic pathways that are broadly dysregulated in Nampt-rod/-rod retinas, including protein 
biosynthesis, propanoate metabolism, and the citric acid cycle, among others (Figure 2.4E). 
To confirm that these effects on mitochondrial function were indeed related to loss of 




pharmacological NAMPT inhibitor FK866 (20 µM) and measured reductive capacity to 
approximate metabolic activity. NAMPT inhibition caused considerable reduction of 
photoreceptor cell reductive capacity. By 24 hours, FK866-treated cells had roughly 40% of the 
reductive capacity of vehicle-treated cells (Figure 2.5A). By 48 hours, there was an even more 
dramatic effect with reductive capacity reduced down to ~20% (Figure 2.5B). Although there 
was no cell death at 24 hours (Figure 2.5C), this loss of reductive capacity ultimately led to cell 
death by 48 hours (Figure 2.5D). This finding highlights that metabolic dysfunction, as 
represented by a decrease in reductive capacity, precedes cell death. 
Since we observed that exogenous NMN supplementation rescued retinal function in 
Nampt-rod/-rod and Nampt-cone/-cone mice, we tested whether NMN supplementation could rescue the 
deleterious effects of NAMPT inhibition in photoreceptor cells. Our results demonstrate that 
providing FK866-treated photoreceptors with NMN (100 µM) could completely restore normal 
reductive capacities at 24 hours and at 48 hours and prevent subsequent cell death (Figures 
2.5A, 2.5B, and 2.5D). These results provide strong evidence for the importance of NAMPT-
mediated NAD+ biosynthesis in photoreceptors since we demonstrate that bypassing the 
NAMPT-catalyzed reaction could restore normal reductive capacity and prevent cell death. 
To determine whether these dramatic effects of NAMPT inhibition were unique to 
photoreceptors, we tested the effects of FK866 (20 µM) on the reductive capacity and cell 
survival of ARPE-19 RPE cells. Of interest, an identical dose of FK866 had no effect on the 
reductive capacity of RPE cells at 24 hours and only a modest albeit statistically significant 
effect on reductive capacity at 48 hours (data not shown). Remarkably, FK866 did not reduce 
RPE cell survival at either 24 or 48 hours (data not shown), demonstrating that RPE cells are 




results suggest that photoreceptors are uniquely vulnerable to impairment of NAMPT-mediated 
NAD+ biosynthesis and implicate this pathway as a master regulator of photoreceptor 
metabolism and survival. 
 
NAMPT inhibition causes rapid NAD+ depletion, leading to an ATP crisis 
To further characterize the effects of NAMPT inhibition, we measured NAD+ levels in 
photoreceptor cells after treatment with FK866 (20 µM). As expected, by 6 hours, FK866-treated 
photoreceptor cells contained significantly less total NAD+ compared to vehicle-treated cells 
plated at the same density (Figure 2.5E). Exogenous NMN supplementation (100 µM) returned 
NAD+ back to near-normal levels (Figure 2.5E). After 24 hours, there were undetectable levels 
of NAD+ in FK866-treated cells compared to vehicle-treated cells (Figure 2.5F). Similar to the 
6-hour time point, exogenous NMN supplementation for 24 hours prevented FK866-associated 
NAD+ depletion, bringing NAD+ back to even higher levels compared to vehicle-treated cells 
(Figure 2.5F). We interpret these results to indicate that NAMPT inhibition causes rapid NAD+ 
deficiency, which likely contributes to the metabolic dysfunction described above. 
To further characterize the connection between NAD+ depletion and cell death, we 
investigated the time course of NAD+ depletion and its effect on ATP production by 
simultaneously measuring NAD+ and ATP content in photoreceptor cells at various times after 
treatment with FK866 (20 µM). As above, we found that FK866 caused rapid NAD+ deficiency. 
By 6 hours, NAD+ levels were down to ~50% of their original levels (Figure 2.5G). NAD+ 
depletion continued rapidly, dropping to ~15% by 12 hours and to undetectable levels by 24 
hours (Figure 2.5G). NAMPT inhibition also caused ATP depletion, but ATP levels did not 




levels by 12 hours (Figure 2.5G). By 24 hours however, ATP levels had dropped down to ~10% 
of the original levels (Figure 2.5G). The temporal relationship between NAD+ and ATP 
depletion suggests that the ATP crisis is a downstream effect of NAD+ deficiency-associated 
metabolic dysfunction. 
To confirm the connection between NAD+ availability, ATP content, metabolic function, 
and cell survival, we also measured NAD+ and ATP levels in RPE cells after NAMPT inhibition. 
Consistent with the mild effects on metabolic function and the lack of effect on cell survival, 24 
hours of FK866 treatment (20 µM) caused only a ~60% reduction in total NAD+ levels (data not 
shown), a smaller effect than that observed after 24 hours of FK866 treatment in photoreceptor 
cells. This intermediate decrease in total NAD+ levels was accompanied by a concomitant 
increase in ATP levels (data not shown), drastically different from the severe ATP depletion 
exhibited by photoreceptor cells. These findings suggest that photoreceptor cells are more 
vulnerable to perturbations in NAD+ biosynthesis compared to other non-photoreceptor eye cells, 
such as RPE cells. 
 
NAMPT inhibition impairs basal metabolism and the normal response to metabolic stress 
The rapid decline of ATP in photoreceptor cells within 24 hours of FK866 treatment 
suggests that NAMPT inhibition causes significant metabolic dysfunction. To characterize what 
elements of metabolic function were impaired, we treated photoreceptor cells with FK866 (20 
µM) and profiled various aspects of metabolism by measuring oxygen consumption rate (OCR) 
as a measure of aerobic respiration and extracellular acidification rate (ECAR) as a measure of 




various conditions of stress induced by sequential treatments with oligomycin, carbonyl cyanide-
4-(trifluoromethoxy)phenylhydrazone (FCCP), and antimycin A/rotenone. 
At baseline, FK866-treated photoreceptor cells exhibited reduced OCR and ECAR 
(Figures 2.5H and 2.5I), indicating that NAMPT inhibition caused reduced basal oxidative 
respiration and basal glycolytic flux. While vehicle-treated cells responded appropriately to the 
ATP synthase inhibitor oligomycin by shifting toward glycolytic metabolism (reduced OCR; 
increased ECAR), FK866-treated photoreceptor cells were unable to shift toward glycolytic 
metabolism (Figures 2.5H and 2.5I). Moreover, while vehicle-treated cells responded 
appropriately to the ionophore FCCP by elevating their oxidative respiration (increased OCR), 
FK866-treated photoreceptor cells were unable to accelerate oxidative respiration in response to 
metabolic stress (Figure 2.5H). NMN supplementation restored normal baseline metabolism and 
the appropriate responses to stress (Figures 2.5H and 2.5I), confirming that these phenotypes 
were specific to NAD+ deficiency. 
To confirm that these effects on metabolic function were specific to NAMPT inhibition, 
we performed Nampt knockdown in photoreceptor cells. Partial reduction of NAMPT-mediated 
NAD+ biosynthesis through Nampt knockdown in photoreceptor cells caused a reduction in 
NAD+ levels (data not shown) within 24 hours after knockdown. Although this intermediate 
reduction in NAD+ did not affect reductive capacity or cell survival at the early 48-hour time 
point, it did impair the ability of photoreceptor cells to maximally accelerate oxidative 
respiration in response to FCCP (data not shown), further reinforcing the importance of 





Taken together, these data confirm the importance of NAMPT-mediated NAD+ 
biosynthesis for maintaining photoreceptor glycolytic and mitochondrial function – both at 
baseline and in response to metabolic stress – and highlight a NAMPT-specific effect due to the 
ability of NMN to restore normal metabolic responses. Importantly, we observed these signs of 
metabolic dysfunction after 24 hours of FK866 treatment prior to when we observed the effects 
on photoreceptor cell viability. Once again, these results highlight that glycolytic and 
mitochondrial dysfunction precede and therefore likely cause photoreceptor cell death. 
 
NAD+ deficiency causes NAD-IDH dysfunction 
Our in vitro and in vivo results suggest that there are defects in oxidative metabolism in 
photoreceptors under conditions of NAD+ deficiency. To more specifically characterize these 
defects in oxidative metabolism, we tested the activity of three enzymes of the Krebs cycle that 
require NAD+ as a coenzyme: NAD+-dependent isocitrate dehydrogenase (NAD-IDH/IDH3), 
alpha-ketoglutarate dehydrogenase (AGDH), and malate dehydrogenase (MDH). The fact that 
these enzymes require NAD+ as a coenzyme provides the opportunity to determine whether their 
enzymatic dysfunction is caused solely by loss of NAD+ as a coenzyme. If loss of NAD+ as a 
coenzyme were solely responsible for enzymatic dysfunction, we would expect to be able to 
restore enzymatic function simply by providing sufficient NAD+ to the reaction mixture. 
We found that NAD-IDH activity was significantly lower in rods isolated from Nampt-
rod/-rod retinas compared to those isolated from NamptF/F retinas, even when sufficient NAD+ was 
supplied in the reaction (Figure 2.5J) despite similar NAD-IDH expression levels (Figure 
2.5K). These findings suggest that NAD-IDH dysfunction cannot be explained by loss of NAD+ 




rescued by NAD+ (Figures 2.5L and 2.5M), indicating selective enzymatic dysfunction. These 
findings not only characterize one specific aspect of mitochondrial dysfunction but also suggest 
that NAD+ plays important roles on regulating metabolism in addition to its role as a coenzyme. 
 
SIRT3 and SIRT5 play important roles in photoreceptor survival 
In addition to serving as a coenzyme for crucial steps of glycolysis and the Krebs cycle, 
NAD+ also serves as a cosubstrate for NAD+-consuming enzymes, including the sirtuins. Of the 
seven sirtuin family members, three of them, SIRT3, SIRT4, and SIRT5, are known to regulate 
mitochondrial function (Laurent et al., 2013; Yang et al., 2007; Zhang et al., 2015). Because 
other sirtuin family members have been shown to play crucial roles in regulating the survival of 
retinal cells (Jaliffa et al., 2009; Silberman et al., 2014) and because sirtuins depend on NAD+ 
availability for optimal function (Satoh and Imai, 2014), we hypothesized that NAD+ deficiency 
may also impair mitochondrial sirtuin activity, contributing to mitochondrial dysfunction. 
To determine whether the mitochondrial sirtuins are essential for photoreceptor survival, 
we performed individual and combined knockdown of SIRT3, SIRT4, and SIRT5 in 
photoreceptor cells. Individual knockdown of SIRT3 and SIRT5 caused significant reduction in 
reductive capacity compared to knockdown by negative control (Figure 2.6A). Interestingly, 
individual knockdown of SIRT4 did not diminish reductive capacity, highlighting the specificity 
of the effect of SIRT3 and SIRT5 (Figure 2.6A). Combined SIRT3 and SIRT5 knockdown had a 
synergistic effect, leading to significantly lower reductive capacity compared to either single 
knockdown alone (Figure 2.6A). Of note, NMN was not able to rescue the effect on reductive 
capacity in the SIRT3/SIRT5 double knockdown (Figure 2.6A), suggesting that exogenous 




This decline in reductive capacity secondary to SIRT3/SIRT5 knockdown was also 
accompanied by progressive cell death. Individual knockdown of SIRT3 and SIRT5 caused 
significant reduction in cell survival compared to knockdown by negative control (Figure 2.6B). 
Again, individual knockdown of SIRT4 had no effect on cell viability (Figure 2.6B), 
highlighting the specificity of the SIRT3/SIRT5 effect. Once again, combined SIRT3 and SIRT5 
knockdown had a more profound effect on cell death compared to either individual knockdown 
alone (Figure 2.6B). Consistently, NMN supplementation did not rescue the cell death caused by 
combined SIRT3/SIRT5 double knockdown (Figure 2.6B). 
To test whether loss of SIRT3 and SIRT5 causes mitochondrial dysfunction similar to 
that caused by NAD+ deficiency, we performed individual and combined SIRT3 and SIRT5 
knockdowns in photoreceptors and measured the NAD-IDH activity 24 hours after transfection. 
We found that knocking down SIRT3, SIRT5, or both SIRT3/SIRT5 in photoreceptor cells 
recapitulated NAD-IDH dysfunction (Figure 2.6C). The fact that SIRT3 and SIRT5 
knockdowns phenocopy the NAD-IDH dysfunction observed in rods isolated from Nampt-rod/-rod 
retinas suggests that SIRT3 and SIRT5 may play a role in governing the metabolic dysfunction 
associated with NAD+ deficiency. 
To test the role of SIRT3 and SIRT5 in retinal function in vivo, we tested mice lacking 
SIRT3 and SIRT5. Both SIRT3KO and SIRT5KO mice have normal-appearing fundi on 
biomicroscopy and normal retinal function on ERG compared to strain-matched controls (data 
not shown). However, since many studies report that SIRT3 and SIRT5 regulate many of the 
same protein targets and even the same lysine residues within the same protein (Hebert et al., 




2012; Still et al., 2013), it is possible that SIRT3 and SIRT5 can compensate for one another. To 
test this possibility, we also tested mice lacking multiple mitochondrial sirtuins. 
Although SIRT3KOSIRT5KO mice had normal retinal function at baseline (data not 
shown), we could not yet conclude that SIRT3 and SIRT5 are inessential for retinal function 
since previous studies have reported that mice lacking mitochondrial sirtuins rarely show striking 
phenotypes (Lombard et al., 2007; Yu et al., 2013) until they are challenged by specific stimuli 
such as fasting or a high-fat diet (Hirschey et al., 2011). To this end, we tested whether 
SIRT3KOSIRT5KO mice are more vulnerable to retinal degeneration after exposure to light. We 
found that SIRT3KOSIRT5KO mice were strikingly more vulnerable to retinal degeneration upon 
light stress compared to SIRT3hetSIRT5het controls as manifested by retinal dysfunction 
measured by ERG (Figures 2.6D, 2.6E, and 2.6F) four days after light treatment. Interestingly, 
SIRT3hetSIRT5KO and SIRT3KOSIRT5het mice demonstrated an intermediate degenerative 
phenotype (Figures 2.6D, 2.6E, and 2.6F), supporting the notion that SIRT3 and SIRT5 
synergistically regulate mitochondrial function in photoreceptors. Together, these results provide 
strong evidence that SIRT3 and SIRT5 not only are important for maintaining photoreceptor 
survival but also have distinct, non-redundant roles in regulating retinal homeostasis. 
 
NAMPT inhibition causes SIRT3 dysfunction 
Since we found that SIRT3 and SIRT5 are essential for photoreceptor survival, we sought 
to determine whether NAD+ deficiency caused by NAMPT inhibition impairs SIRT3 and SIRT5 
function in photoreceptor cells. Since SIRT3 regulates predominantly protein acetylation 
(Parihar et al., 2015) and SIRT5 regulates predominantly protein succinylation, malonylation, 




2014), we tested whether NAMPT inhibition modulates the acylation of mitochondrial proteins 
in photoreceptor cells. We found that mitochondrial lysates generated from photoreceptor cells 
treated with FK866 (20 µM) for 24 hours showed obvious hyperacetylation (Figures 2.7A and 
2.7B), indicating SIRT3 dysfunction. Normal acetylation patterns were restored with NMN 
(Figures 2.7A and 2.7B), confirming that this hyperacetylation was specific to NAMPT 
inhibition. Although there were clear acetylation changes, these mitochondrial lysates 
demonstrated only modest changes in succinylation (Figures 2.7C and 2.7D) and no obvious 
differences in malonylation or glutarylation (data not shown), suggesting that NAD+ deficiency 
primarily impairs SIRT3 function. 
To confirm that these effects were caused by NAMPT inhibition rather than being 
secondary to metabolic dysfunction, we measured the activity of SIRT3 and SIRT5 in the 
mitochondrial lysates generated from FK866-treated photoreceptor cells. Consistent with our 
Western Blots, mitochondrial lysates generated from FK866-treated photoreceptor cells had a 
significant reduction in SIRT3 activity compared to mitochondrial lysates generated from 
vehicle-treated cells (Figure 2.7E). There was, however, no difference in SIRT5 activity (Figure 
2.7F). Taken together, these results demonstrate that NAD+ deficiency leads to dysregulation of 
the mitochondrial acylome primarily through impairment of SIRT3 function. Since we show that 
SIRT3 is important for photoreceptor survival, this NAD+ deficiency-associated impairment of 
SIRT3 activity likely contributes to the mitochondrial dysfunction observed in photoreceptors 
lacking Nampt, providing additional mechanistic evidence for why NAMPT-mediated NAD+ 






NAD+ has numerous functions in diverse biological processes including metabolism, 
circadian rhythms, aging, and neurodegeneration (Alano et al., 2010; Garten et al., 2009; Gerdts 
et al., 2015; Imai and Yoshino, 2013; Mouchiroud et al., 2013; Nakahata et al., 2009; Ramsey et 
al., 2009; Stein et al., 2014; Zhou et al., 2015). In the current study, we demonstrate that 
NAMPT-mediated NAD+ biosynthesis is indispensable for photoreceptor survival and vision. 
Using loss-of-function approaches, we show that disrupting NAMPT-mediated NAD+ 
biosynthesis in rod and cone photoreceptors leads to photoreceptor death, retinal degeneration, 
and blindness. By testing the effects of NAMPT inhibition on non-photoreceptor cells, we 
confirm that photoreceptors are uniquely susceptible to perturbations in NAD+ biosynthesis. 
Moreover, we demonstrate that, in photoreceptors, loss of NAMPT-mediated NAD+ 
biosynthesis leads to NAD+ deficiency, significant glycolytic and mitochondrial dysfunction 
under basal conditions, and the inability to respond appropriately to metabolic stress, which 
ultimately lead to photoreceptor death and retinal degeneration. Corresponding with this 
energetic failure, metabolic profiling of retinas from Nampt-rod/-rod mice revealed dysregulation of 
numerous metabolic pathways. Of interest, there was a trend (P = 0.0704) toward dysregulation 
of the citric acid cycle, a key pathway in oxidative metabolism. The trends toward accumulation 
of various acylcarnitine species also support a failure of Krebs cycle efficiency. These hallmarks 
of metabolic dysfunction could be identified prior to cell death and vision loss, supporting the 
possibility of probing mitochondrial function to predict subsequent photoreceptor death (Perron 
et al., 2013). These findings are interesting, especially considering recent studies that show that 
photoreceptors have limited mitochondrial reserve capacity, which may make them susceptible 




Krebs cycle cause broad energetic failure and contribute to downstream defects in numerous 
metabolic pathways, such as protein biosynthesis and propanoate metabolism. Further studies are 
necessary to explore the precise connection between these phenomena. 
Our results also identify that NAD+ deficiency leads to selective enzymatic dysfunction 
and that cell death is unlikely to be caused by loss of NAD+ as a coenzyme alone. When we 
tested the activity of the three NAD+-dependent enzymes of the Krebs cycle in rods isolated from 
Nampt-rod/-rod retinas, only NAD-IDH activity could not be rescued by providing sufficient NAD+ 
as a coenzyme, while the activity of AGDH and MDH were restored by providing exogenous 
NAD+. This result stresses the importance of NAD-IDH in maintaining metabolic homeostasis in 
photoreceptors. In support, the retina has been shown to be highly dependent on NAD-IDH and 
exquisitely sensitive to defects in NAD-IDH function, such that mutations in NAD-IDH that 
impair its catalytic activity cause RP (Hartong et al., 2008). Of significant interest, these RP 
patients have normal NADP+-dependent IDH (i.e., NADP-IDH or IDH1/IDH2) activity and no 
other manifestations of disease despite the fact that they carry this mutation in all cells of their 
body (Hartong et al., 2008). This finding suggests that in contrast with most organ systems, the 
retina uniquely relies on the NAD+-dependent form of IDH (Hartong et al., 2008). 
We further demonstrate that SIRT3 and SIRT5 both play important roles in photoreceptor 
survival and that NAD+ deficiency leads predominately to SIRT3 dysfunction. Our results agree 
with past studies reporting that other sirtuin family members, including SIRT1 (Jaliffa et al., 
2009) and SIRT6 (Silberman et al., 2014), play roles in survival of photoreceptors and other 
retinal cells. Interestingly, we demonstrate that the deleterious effects of SIRT3 and SIRT5 
deletion are synergistic. These findings strongly suggest that SIRT3 and SIRT5 are not redundant 




the same lysine residues within the same proteins (Hebert et al., 2013; Park et al., 2013; Rardin 
et al., 2013a; Rardin et al., 2013b; Schwer et al., 2009; Sol et al., 2012; Still et al., 2013). 
Based on our results, we hypothesize that SIRT3 dysfunction caused by NAD+ deficiency 
may contribute to mitochondrial dysfunction by causing aberrant hyperacetylation of key 
mitochondrial proteins, such as NAD-IDH. The possibility that SIRT3 dysfunction is linked to 
decreased NAD-IDH activity is supported not only by our ability to recapitulate NAD-IDH 
dysfunction with SIRT3 knockdown but also by the fact that NAD-IDH has been identified as a 
target of SIRT3 (Hebert et al., 2013; Rardin et al., 2013b; Schwer et al., 2009; Sol et al., 2012; 
Still et al., 2013). Further studies are needed to explore this possibility and to confirm these 
observations in vivo, perhaps using new technologies such as CRISPR/Cas9 to delete Nampt 
selectively from photoreceptors. 
 Cumulatively, these findings provide unique insights that point to the dominant 
mammalian NAD+ biosynthesis pathway as a master regulator of photoreceptor metabolism. 
Human retinal degenerations encompass a broad spectrum of diseases that include seemingly 
unrelated disorders such as LCA and RP, which have been associated with mutations in enzymes 
involved in NAD+ biosynthesis (Chiang et al., 2012; Falk et al., 2012; Koenekoop et al., 2012; 
Perrault et al., 2012) and the Krebs cycle (Hartong et al., 2008). Despite these genetic insights, 
the mechanisms underlying these conditions and what ultimately causes photoreceptor 
degeneration in these genotypically diverse disorders are poorly understood. We propose a 
model linking NAD+ biosynthesis, SIRT3/SIRT5, and metabolism in photoreceptors, which may 
connect these diverse retinal neurodegenerations at the molecular level. 
Remarkably, our studies also demonstrate that bypassing the NAMPT-catalyzed reaction 




despite NAMPT inhibition and reduce photoreceptor death in Nampt-rod/-rod mice. In 
photoreceptor cells subjected to NAMPT inhibition, NMN supplementation prevented metabolic 
dysfunction and cell death by restoring normal basal glycolytic and mitochondrial function and 
the ability to respond appropriately to metabolic stress. This therapeutic effect is likely explained 
by the importance of NAD+ not only to perform its coenzyme role in various steps of the Krebs 
cycle and glycolysis but also to maintain optimal SIRT3 activity. We show that multiple mouse 
models of retinal dysfunction, including light-induced degeneration, STZ-induced diabetic 
retinopathy, and age-associated retinal dysfunction all exhibit early retinal NAD+ deficiency. 
Moreover, the retinal dysfunction associated with light-induced degeneration can be partially 
rescued with NMN. These findings offer powerful therapeutic avenues for degenerative diseases 
of the eye and are supported by past studies exploring the therapeutic applications of NAD+ 
supplementation in light-induced degeneration (Bai and Sheline, 2013), noise-induced hearing 
loss (Brown et al., 2014), and high-fat diet- and age-induced metabolic complications (Canto et 
al., 2012; Ramsey et al., 2008; Stein and Imai, 2014; Yoshino et al., 2011). 
Once successfully implemented, this treatment strategy would be far-reaching since it 
could be implemented for multiple diseases with diverse pathogenic mechanisms, including not 
only inherited forms of retinal degenerations but also other blinding diseases characterized by a 
final pathway of photoreceptor death such as age-related macular degeneration and diabetic 
retinopathy. Given the global importance of NAD+ biosynthesis and mitochondrial dysfunction 
in neurons, our findings may also be broadly relevant to other systemic neurodegenerative 







Mice. All animal experiments were approved by the Animal Studies Committee and performed 
in accordance with the Washington University School of Medicine Animal Care and Use 
guidelines. Namptflox/flox (NamptF/F) mice were previously characterized (Rongvaux et al., 2008) 
and were provided by Dr. Shin-ichiro Imai. To generate mice lacking Nampt specifically from 
rod photoreceptors, we crossed NamptF/F mice with mice carrying one copy of the Rhodopsin-
iCre75 transgene, which were provided by Dr. Ching-Kang Jason Chen and have been 
previously characterized (Li et al., 2005). To generate mice lacking Nampt specifically from 
cone photoreceptors, we crossed NamptF/F mice with mice carrying one copy of the human 
red/green pigment-Cre (HRGP-Cre) transgene, which were provided by Dr. Yun Le and have 
been previously characterized (Le et al., 2004). We received 6-month-old and 18-month-old 
wild-type C57BL/6J mice from the National Institutes on Aging (Bethesda MD) and purchased 
streptozotocin (STZ)-induced hyperglycemic mice (C57BL/6J) from Jackson Laboratories (Bar 
Harbor ME). We also purchased SIRT3-/-, SIRT5-/-, and the appropriate strain-matched wild-type 
mice (129S1/SvImJ for SIRT3-/- and B6129SF2/J for SIRT5-/-) from Jackson Laboratories. 
 
Cells and reagents. We routinely cultured 661W cone photoreceptor-like cells, provided by Dr. 
Muayyad Al Ubaidi (Tan et al., 2004), in Dulbecco’s Modified Eagle Medium with 1 g/L 
glucose and 110 mg/L sodium pyruvate (DMEM; Thermo Fisher, Carlsbad CA) supplemented 
with 10% Fetal Bovine Serum (FBS; Sigma, St. Louis MO) and 1% penicillin-streptomycin 
(Thermo Fisher, Carlsbad CA). We prepared stock solutions of FK866 (Santa Cruz 




(NMN) from Sigma (St. Louis MO) and dissolved it directly in cell culture media, prepared as 
described above. 
 
Real-time PCR in rod-enriched samples. We generated rod-enriched samples by vortexing 
dissected whole retinas for 60 seconds at medium speed and centrifuging the resulting 
supernatant at 12,800 g for 10 minutes. We extracted total RNA from the resulting pellet with the 
RNeasy Mini Kit (Qiagen, Valencia CA), prepared cDNA with the High Capacity cDNA 
Reverse Transcription Kit (Life Technologies, Grand Island NY), and performed PCR 
amplification of cDNA using Taqman probe-based gene expression assays (Life Technologies, 
Grand Island NY) as described previously (Kelly et al., 2007). We used probes for Nampt 
(Mm01293560_m1) and Idh3a (Mm00499674_m1) normalized to ActB (Mm00607939_s1) or 
Rho (Mm01184405_m1) with the ΔΔCT method. 
 
Retinal imaging. We performed digital color fundus photography using the Micron IIITM animal 
fundus camera (Phoenix Research Laboratories, Pleasanton CA). Prior to fundus imaging, we 
anesthetized mice with an intraperitoneal injection of 86.9 mg/kg ketamine and 13.4 mg/kg 
xylazine and administered 1.0% tropicamide eye drops (Bausch & Lomb, Tampa FL) to dilate 
the pupils. 
 
Histology and immunohistochemistry. After euthanizing the mice, we enucleated the eyes and 
fixed them overnight in 10% formalin. Next, we embedded the eyes in methacrylate and 
prepared eight to ten sections of 6-8 µm thickness cut at different planes for each eye. We 




St. Louis MO), and rabbit anti-cone arrestin (AB15282; Millipore, Billerica MA). We acquired 
images with an Olympus FV1000TM upright confocal microscope with UV-sensitive (405), 
multi-Argon (458, 488 & 513) & Helium-Neon (543 & 633) lasers, and a Plan Apo N 60x oil 
objective (N.A.=1.42). 
 
Electroretinography. We performed electroretinography (ERG) as previously described 
(Hennig et al., 2013) by using the UTAS-E3000 Visual Electrodiagnostic System running EM 
for Windows (LKC Technologies, Gaithersburg MD). We extracted quantitative measurements 
from the ERG waveforms using an existing Microsoft Excel macro that defines the a-wave 
amplitude as the difference between the average pre-trial baseline and the most negative point of 
the average trace and defines the b-wave amplitude as the difference between this most negative 
point to the highest positive point, without subtracting oscillatory potentials. 
 
Photopic visual acuity. We measured mouse photopic visual acuity under standard photopic 
conditions (1.85 log cd m-2) by testing the optokinetic reflex with the OptoMotryTM System 
(CerebralMechanics) as described previously (Kolesnikov et al., 2011; Umino et al., 2008). 
 
Transmission electron microscopy. To perform transmission electron microscopy, we dissected 
enucleated eyes to remove the cornea and lens, and fixed eye cups for 4 hours at room 
temperature in 2% paraformaldehyde/2.5% glutaraldehyde (Polysciences, Warrington PA) 
diluted in 100 mM sodium cacodylate (pH 7.2). We then washed the fixed eye cups in cacodylate 
buffer and post-fixed them in 1% osmium tetroxide (Polysciences) for 1 hour. We then rinsed the 




uranyl acetate (Ted Pella, Redding CA) for 1 hour. Following several rinses, we dehydrated the 
stained eye cups with a graded series of ethanol solutions and embedded them in Eponate 12 
resin (Ted Pella). We cut 95 nm sections with a Leica Ultracut UCT ultramicrotome (Leica 
Microsystems, Bannockburn IL), stained the sections with uranyl acetate and lead citrate, and 
imaged them on a JEOL 1200 EX transmission electron microscope (JEOL USA, Peabody MA) 
equipped with an AMT 8 megapixel digital camera (Advanced Microscopy Techniques, Woburn 
MA). 
 
Metabolomic analysis. We isolated retinas at the same time of day after restricting oral nutrient 
intake for 4 hours. We pooled 6 retinas per group and snap-froze them in liquid nitrogen. We 
then added ammonium bicarbonate-buffered solution to the tissue pellets and transferred these 
tissue suspensions to tubes for subsequent metabolite extraction. We extracted intracellular 
metabolites and culture media samples into cold methanol:acetonitrile (ACN):water (H2O), dried 
them, derivatized them to their tert-butyldimethylsilyl esters (tBDMS), and then analyzed them 
on an Agilent 7200 GC-quadrupole-time of flight (QTOF)-MS operating in electron impact 
ionization mode. We dried an aliquot of each extract and dissolved it in ACN:H2O for 
subsequent LC-QTOF-MS analysis. We performed metabolite set enrichment analysis with 
MetaboAnalyst 3.0 (Xia et al., 2015) by inputting the list of dysregulated metabolites with a 
statistically significant difference (corrected P-value < 0.05) and a fold change > 1.10. These 
data were processed with the over representation algorithm and the metabolic pathway-





Reductive capacity assay. To quantify reductive capacity, we used the Cell Proliferation 
Reagent WST-1 (Roche Applied Science, Indianapolis IN) according to manufacturer’s 
instructions. In short, we washed cells once with PBS after the desired treatment and replaced the 
media with fresh media containing the WST-1 assay solution at a 1:10 dilution. After 2 hours of 
incubation at 37°C, we measured absorbance at 450 nm with the SpectraMax 190 Absorbance 
Microplate Reader (Molecular Devices, Sunnyvale CA). 
 
Cell survival assay. To determine cell survival, we used the cell-permeant dye calcein AM 
(Thermo Fisher, Carlsbad CA) according to manufacturer’s instructions. In short, we washed 
cells once with PBS after the desired treatment and replaced the media with calcein AM diluted 
in PBS (working concentration of 2 µM). After 30 minutes at 37°C, we measured fluorescence at 
485 nm excitation/520 nm emission with the Infinite 200 PRO (Tecan, Männedorf Switzerland). 
 
Quantification of NAD+ & ATP levels with HPLC. To quantify the NAD+ and ATP levels of 
mouse retina, pooled rod-enriched isolates, or 661W cells, we performed reverse-phase high-
performance liquid chromatography (HPLC) as described previously (Yoshino and Imai, 2013). 
We quantified NAD+ and ATP levels based on the peak area on the HPLC spectrogram relative 
to a standard curve, and normalized these values to tissue weights for retinas, number of retinas 
for rod-enriched isolates, or based on cell number. 
 
OCR and ECAR measurements. We performed detailed metabolic characterization of 661W 
cells after NAMPT inhibition using an XF96 Extracellular Flux Analyzer (Seahorse Bioscience, 




µL of prewarmed bicarbonate-free DMEM (pH 7.4). After 30-60 minutes in a non-CO2 
incubator, we simultaneously measured oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) to quantify oxidative respiration and glycolytic flux, respectively, both 
at baseline and after sequential treatments of 1.5 µM oligomycin, 1.0 µM carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone (FCCP), and a combination of 1.0 µM antimycin A and 1.0 
µM rotenone. Each 5-minute measurement period was preceded by 2 minutes of mixing and a 1-
minute pause; we made 3 sequential measurements per treatment condition. 
 
SIRT3-5 and Nampt knockdown in 661W cells. We transfected 661W cells with custom LNA 
longRNA GapmeRs reagents (Exiqon, Woburn MA) targeting SIRT3, SIRT4, or SIRT5 at a final 
concentration of 100 nM, and commercially available siRNA targeting Nampt (Mm_Pbef1_5; 
Qiagen, Valencia CA) at a final concentration of 50 nM. In short, we seeded 661W cells and 
allowed them to adhere for 30 minutes. We prepared the transfection complexes by incubating 
the appropriate GapmeR/siRNA with Lipofectamine RNAiMAX transfection reagent 
(Invitrogen, Grand Island NY) for 5 minutes at room temperature (1.0 µl or 2.4 µl of RNAiMAX 
per well for the 96-well and 24-well plate formats, respectively). We confirmed knockdown 
efficiency with real-time PCR. 
 
Light-induced degeneration (LID). We performed light-induced degeneration as described 
previously (Grimm and Reme, 2013). In short, we dilated pupils with two sequential drops of 
1.0% atropine sulfate and 1.0% tropicamide (Bausch & Lomb, Tampa FL), and then exposed the 
mice to 13,000 lux from fluorescent lights suspended directly over the mice. We placed the mice 




dilated pupils with two additional drops every 2 hours. We assessed retinal function 4 days 
following light-induced degeneration by ERG as described above. All the mice we tested carried 
the RPE65Leu/Leu variant, making them equally vulnerable to light-induced degeneration (Wenzel 
et al., 2001). 
 
Krebs cycle enzymatic activity assays. We performed retinal dissociation by incubating 
dissected retinas in 12 U/ml papain (Sigma, St. Louis MO) and 5 mM L-cysteine in DMEM for 
30 minutes on a small vibrating aquarium pump at room temperature. After washing away 
residual papain with 5 exchanges to fresh DMEM, we triturated the samples with fire-polished 
Pasteur pipets. We then separated rod photoreceptors with the EasySEP Mouse PE Positive 
Selection Kit (Stem Cell Technologies, Vancouver Canada) and PE-conjugated anti-CD73 
antibodies (Miltenyi Biotec, Bergisch Gladback Germany). We measured the enzymatic activity 
of NAD+-dependent isocitrate dehydrogenase (NAD-IDH/IDH3), alpha-ketoglutarate 
dehydrogenase (AGDH), and malate dehydrogenase (MDH) in these rods with assay kits from 
Sigma (St. Louis MO) according to the manufacturer’s instructions. We normalized enzymatic 
activity to total protein and/or viable rod cell number. 
 
Western Blotting for mitochondrial protein acylation. We isolated mitochondria from 661W 
cells as described previously (Frezza et al., 2007). We denatured mitochondrial lysates in 
NuPAGE LDS Sample Buffer and NuPAGE Sample Reducing Agent (Thermo Fisher, Carlsbad 
CA) for 10 minutes at 70°C, loaded them into 4-12% Novex Bis-Tris Protein Gels, and then ran 
them at 50 V for 15 minutes followed by 150 V for 60 minutes. We transferred the gel to a 0.2 




Tris-base, 10% methanol) for 60 minutes at a constant current of 400 mA. We blocked the 
membranes for 60 minutes at room temperature with 5% (w/v) bovine serum albumin (BSA; 
Sigma) in TBS with 0.05% Tween-20 (0.05% TBST). We then stained the membranes overnight 
at 4°C with 1:1,000 anti-acetyllysine (#9441; Cell Signaling Technology, Danvers MA), 1:1,000 
anti-succinyllysine (PTM-401; PTM BioLabs, Chicago IL), 1:1,000 anti-malonyllysine (PTM-
901; PTM BioLabs), or 1:1,000 anti-glutaryllysine (PTM-1151; PTM BioLabs) diluted in 
blocking buffer. We then washed the membranes and incubated them for 60 minutes at room 
temperature with the appropriate secondary antibody conjugated to either IRDye 800CW or 
IRDye 680LT (LI-COR, Lincoln NE) diluted 1:5,000 in blocking buffer. We detected proteins 
and analyzed the band densities with the Odyssey Infrared Imaging System (LI-COR). We 
normalized protein loading per lane with the Pierce BCA Protein Assay Kit (Thermo Fisher, 
Carlsbad CA) and used anti-COX IV (4D11-B3-E8) antibody (#11967; Cell Signaling 
Technology) as the loading control. 
 
SIRT3 and SIRT5 activity assays. We measured the SIRT3 activity and SIRT5 activity of 
mitochondrial isolates from 661W cells with commercially available kits (Abcam, Milton 
Cambridge; Enzo Life Sciences, Farmingdale NY; respectively) according to manufacturer’s 
instructions. We did not add exogenous SIRT3/5 or NAD+ to the reaction mixture to allow us to 
accurately quantify native deacylase activity. 
 
Statistics. We performed statistical testing with GraphPad Prism (Version 6.0), using the 




graphically and with the Kolmogorov-Smirnov test and, when necessary, used appropriate non-
parametric alternatives. We defined statistical significance as a P-value < 0.05. 
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Figure 2.1. Nampt-rod/-rod mice exhibit severe retinal degeneration. (A) Rod-specific deletion of Nampt caused 
significant reduction in Nampt mRNA expression from rod-enriched retinal isolates (N=7 isolates/group; Mann-
Whitney U test). (B) Nampt-rod/-rod retinas had lower NAD+ levels than NamptF/F retinas (N=5-8 retinas/group; 2-
tailed, unpaired t-test). (C) Rod-enriched retinal isolates from Nampt-rod/-rod mice had lower NAD+ levels than those 
from NamptF/F mice (N=9-10 pooled samples/group; 1-tailed, unpaired t-test). (D) Representative fundus images 
from Nampt-rod/-rod mice demonstrated severe signs of retinal degeneration including vascular attenuation and optic 
nerve atrophy. (E) Representative retinal sections from Nampt-rod/-rod mice at 6 weeks stained with hematoxylin & 
eosin showed significantly reduced outer nuclear layer thickness (see arrows) with secondary retinal degeneration. 
(F-H) Nampt-rod/-rod mice exhibited impaired retinal function on ERG (N=5 NamptF/F mice/10 Nampt-rod/-rod mice; 2-
way mixed ANOVA with Bonferroni post-hoc test), and reduced photopic visual acuity (I; N=5-6 mice/group; 2-
tailed, unpaired t-test). Graphs depict mean + S.E.M. (A-C, I) or mean ± S.E.M. (F-H) (* P < 0.05; ** P < 0.01; *** 





Figure 2.2. Nampt-cone/-cone mice exhibit cone-specific degeneration. (A) Cone-specific deletion of Nampt caused 
reduced intracellular NAMPT staining (red) in cone photoreceptors stained with cone-arrestin (green) and the 
nuclear DAPI stain (blue). (B) Representative fundus images from Nampt-cone/-cone mice demonstrated retinal pigment 
epithelial cell mottling (arrows) and optic nerve atrophy (arrowhead) consistent with mild retinal degeneration. (C-
E) Nampt-cone/-cone mice also exhibited impaired retinal function on ERG (N=8-10 mice/group; 2-way mixed ANOVA 
with Bonferroni post-hoc test) and reduced photopic visual acuity (F; N=4 mice/group; Mann-Whitney U test). 






Figure 2.3. Exogenous NMN protects against retinal degeneration in mice lacking Nampt and may have efficacy 
against diverse retinal degenerative diseases. (A-C) Nampt-rod/-rod mice receiving daily intraperitoneal injections of 
150 mg/kg NMN beginning at P5 had improved retinal function on ERG (N=12 vehicle/5 NMN; 2-way mixed 
ANOVA with Bonferroni post-hoc test) compared to vehicle-treated mice, consistent with relative preservation of 
the outer nuclear layer on histology (D; see arrows). (E-G) Nampt-cone/-cone mice receiving daily intraperitoneal 
injections of 150 mg/kg NMN beginning at P5 also had improved retinal function on ERG (N=9 vehicle/5 NMN; 2-
way mixed ANOVA with Bonferroni post-hoc test). Retinal NAD+ deficiency is a feature of multiple mouse models 
of retinal dysfunction, including light-induced degeneration (H; N=10-12/group; 2-tailed, unpaired t-test), 
streptozotocin-induced diabetic retinopathy (I; N=5/group; 2-tailed, unpaired t-test), and age-associated retinal 
dysfunction (J; N=5/group; 2-tailed, unpaired t-test). Graphs depict mean + S.E.M. (H-J) or mean ± S.E.M. (A-C, E-





Figure 2.4. NAD+ deficiency disrupts retinal energy homeostasis and can be rescued with exogenous NMN. (A-C) 
Wild-type mice (129S1/SvImJ) receiving intraperitoneal injections of 300 mg/kg NMN were more resilient against 
light exposure (N=8/group; 2-way mixed ANOVA with Bonferroni post-hoc test) compared to vehicle-treated mice. 
(D) Representative electron microscopy images of retinas from 4-week old Nampt-rod/-rod mice revealed mitochondria 
that are rounded, disorganized, and with loss of cristae compared to those from NamptF/F mice. (E) Nampt-rod/-rod 
retinas also exhibited significant disruption of numerous metabolic pathways on metabolite set enrichment analysis. 





Figure 2.5. NAMPT inhibition causes metabolic dysfunction and photoreceptor death. (A-B) NAMPT inhibition 
with 20 µM FK866 caused loss of reductive capacity in 661W cone photoreceptor-like cells by 24 hours and 48 
hours (N=15/group from three independent experiments; 1-way ANOVA with Tukey post-hoc test). (C-D) This 
metabolic dysfunction caused cell death by 48 hours (N=14/group from three independent experiments; 1-way 
ANOVA with Tukey post-hoc test). The effects of NAMPT inhibition were rescued with 100 µM NMN (A-B, D). 
(E) NAMPT inhibition with 20 µM FK866 led to a significant reduction in total NAD+ in photoreceptor cells by 6 
hours, which was restored to near-normal levels with 100 µM NMN (N=3/group; 1-way ANOVA with Tukey post-
hoc test). (F) 24 hours of 20 µM FK866 treatment led to undetectable levels of NAD+ (N.D. = not detected), which 
once again was restored with 100 µM NMN (N=5-7/group). (G) NAMPT inhibition also caused ATP depletion but 
in a delayed time frame relative to NAD+ depletion (N=4/group). (H-I) FK866-treated photoreceptor cells had 
reduced oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) at baseline, impaired ECAR 
acceleration after oligomycin treatment, and impaired OCR acceleration after FCCP treatment (N=15-16/group from 
representative experiment; 2-way mixed ANOVA with Bonferroni post-hoc test). 100 µM NMN restored normal 
metabolic responses (H-I). (J) NAD+-dependent isocitrate dehydrogenase (NAD-IDH/IDH3) activity was reduced in 
rods isolated from Nampt-rod/-rod mice compared to those isolated from NamptF/F mice, even when sufficient NAD+ 
was added to the reaction mixture (N=6/group from three independent experiments; 2-tailed, unpaired t-test) and 
despite similar Idh3a expression levels (K; N=11-13/group from three independent experiments; 2-tailed, unpaired t-
test). (L-M) The activities of other NAD+-dependent enzymes alpha-ketoglutarate dehydrogenase (AGDH; 
N=5/group from three independent experiments; Mann-Whitney U test) and malate dehydrogenase (MDH; 
N=7/group from three independent experiments; 2-tailed, unpaired t-test) in rods from Nampt-rod/-rod mice were 
restored with exogenous NAD+. Graphs depict mean + S.E.M. (A-F, J-M) or mean ± S.E.M. (G-I) (* P < 0.05; ** P 





Figure 2.6. SIRT3 and SIRT5 are essential for photoreceptor survival. (A) Individual SIRT3 and SIRT5 knockdown 
but not SIRT4 knockdown caused significant loss of reductive capacity relative to negative control (NC); combined 
SIRT3/SIRT5 knockdown caused significantly more loss of reductive capacity than individual knockdowns, which 
could not be rescued with NMN (N=6/group from representative experiment; 1-way ANOVA with Tukey post-hoc 
test). (B) Individual SIRT3 and SIRT5 knockdown but not SIRT4 knockdown caused significant cell death relative 
to negative control (NC); combined SIRT3/SIRT5 knockdown caused significantly more cell death than individual 
knockdowns, which could not be rescued with NMN (N=18/group from three independent experiments; 1-way 
ANOVA with Tukey post-hoc test). (C) Individual and combined SIRT3/SIRT5 knockdowns recapitulated NAD-
IDH dysfunction compared to negative control (NC; N=3/group from three independent experiments; 1-way 
ANOVA with Tukey post-hoc test). (D-F) Mice lacking SIRT3 and SIRT5 (SIRT3KOSIRT5KO) were significantly 
more vulnerable to light-induced degeneration (LID) compared to SIRT3hetSIRT5het mice, while SIRT3KOSIRT5het 
and SIRT3hetSIRT5KO mice exhibited intermediate vulnerability to LID (N=5-7 mice/group; 2-way mixed ANOVA 
with Bonferroni post-hoc test). Graphs depict mean + S.E.M. (A-C) or mean ± S.E.M. (D-F) (* P < 0.05; ** P < 
0.01; *** P < 0.001; # P < 0.0001; ^ P < 0.05 relative to both SIRT3KD and SIRT5KD; red: SIRT3hetSIRT5het versus 







Figure 2.7. NAD+ deficiency impairs mitochondrial sirtuin function. (A-B) NAMPT inhibition caused selective 
mitochondrial protein hyperacetylation (N=4 biological replicates from two independent blots; 1-way ANOVA with 
Tukey post-hoc test). (C-D) NAMPT inhibition caused only modest changes in mitochondrial protein succinylation 
(N=6 biological replicates from three independent blots; 1-way ANOVA with Tukey post-hoc test). (E) NAD+ 
deficiency impaired SIRT3 activity (N=6/group; 2-tailed, unpaired t-test) but not SIRT5 activity (F; N=15-16/group; 
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Macrophage aging is pathogenic in numerous diseases, including age-related macular 
degeneration (AMD), a leading cause of blindness in older adults. Although prior studies have 
explored the functional consequences of macrophage aging, less is known about its cellular basis 
or what defines the transition from physiologic aging to disease. Here, we show that despite their 
frequent self-renewal, macrophages from old mice exhibited numerous signs of aging, such as 
impaired oxidative respiration. Transcriptomic profiling of aged murine macrophages revealed 
dysregulation of diverse cellular pathways, especially in cholesterol homeostasis, that manifested 
in altered oxysterol signatures. Although the levels of numerous oxysterols in human peripheral 
blood mononuclear cells and plasma exhibited age-associated changes, plasma 24-
hydroxycholesterol levels were specifically associated with AMD. These novel findings 
demonstrate that oxysterol levels can discriminate disease from physiologic aging. Furthermore, 
modulation of cholesterol homeostasis may be a novel strategy for treating age-associated 






Age-related macular degeneration (AMD) is a leading cause of blindness in adults over 
50 years of age in industrialized nations (van Leeuwen et al., 2003). Early AMD is characterized 
by the presence of lipoproteinaceous deposits or drusen under the retinal pigment epithelium 
(RPE) and/or thickening of Bruch’s membrane. Although early AMD is not always associated 
with vision loss, it is a major risk factor for progression to one of two forms of advanced AMD: a 
dry form, characterized by death of RPE cells called geographic atrophy (GA) that eventually 
leads to death of overlying photoreceptors, or wet (neovascular) AMD, characterized by 
abnormal vascular proliferation underneath the retina called choroidal neovascularization (CNV). 
While both advanced dry and wet AMD can cause vision loss, wet AMD accounts for a 
significant fraction of the vision loss associated with AMD (Ferris et al., 1984) and can often be 
acute and catastrophic. 
The current mainstay therapies for wet AMD focus on combating abnormal angiogenesis 
by blocking vascular endothelial growth factor (VEGF) with targeted anti-VEGF agents. These 
treatments stabilize disease in a majority of patients and significantly improve visual outcomes in 
30-40% of wet AMD patients (Inoue et al., 2016; Kim et al., 2016; Sarwar et al., 2016). 
However, these therapies often require frequent visits for repeated intraocular injections, which 
place a significant burden on patients and caregivers (Haller, 2013). Moreover, repeated 
intravitreal injections are also associated with risks of their own, such as infection, scleral 
thinning, and long-term visual acuity loss due to continued atrophy of the RPE and 
photoreceptors (Sarwar et al., 2016; Zinkernagel et al., 2015). Perhaps more importantly, anti-
VEGF agents do not address the pathophysiology that causes wet AMD (Sene et al., 2015). 




involved in the transition from physiologic aging to AMD and to understand the pathogenesis 
underlying the progression from early to wet AMD, which may lead to novel strategies for 
targeted intervention. 
In the past few decades, we and others have demonstrated that macrophages, key cells of 
the innate immune system, play important roles in the pathogenesis of wet AMD (Apte et al., 
2006; Espinosa-Heidmann et al., 2003; Sakurai et al., 2003). Moreover, it has become 
increasingly clear that the ability of macrophages to polarize to different activation states is an 
important factor affecting whether macrophages promote health or disease (Mosser and Edwards, 
2008). Depending on dynamic tissue signals and the surrounding micro-environment, 
macrophages can polarize to a classical pro-inflammatory (M1-like) phenotype, an alternative 
anti-inflammatory (M2-like) phenotype, or some intermediate between these two extremes (Sica 
and Mantovani, 2012). To further complicate matters, the identity of the specific activators that 
cause macrophage polarization may also affect the macrophage phenotype (Murray et al., 2014). 
Previously, we reported that aged macrophages tend to skew to the anti-inflammatory 
M2-like phenotype and are less able to inhibit abnormal angiogenesis (Kelly et al., 2007). 
Furthermore, aged macrophages exhibit both impairments in cholesterol efflux (Sene et al., 
2013) and abnormalities in IL-10 and downstream STAT3 signaling pathways that contribute to 
this age-associated drift towards M2-like polarization (Nakamura et al., 2015). These age-
associated impairments in cholesterol efflux and other lipid-related pathways may have 
mechanistic consequences in disease pathogenesis (Sene and Apte, 2014). This possibility is 
supported by the fact that polymorphisms in lipid-related genes, such as hepatic lipase (LIPC), 
ATP-binding cassette transporter member 1 (ABCA1), and cholesterol ester transfer protein 




feature of early AMD, are lipid-rich, further supporting our hypothesis that dysregulated lipid 
homeostasis contributes to AMD. Despite these advances, the global programmatic changes that 
occur during macrophage aging need further elucidation. It is also unclear what subset of these 
changes are associated with physiologic aging or are pathologic and contribute to age-associated 
disease. 
In this study, we sought to delineate the cellular pathways involved in macrophage aging 
and identify potential markers that may distinguish age-associated changes that are physiologic 
versus those that promote age-associated disease. Our results suggest that impaired cholesterol 
homeostasis in macrophages is a central process perturbed during aging and that these changes 
lead to changes in oxysterol signatures that can distinguish AMD from physiologic aging. These 
findings may allow physicians to monitor progression of disease with quantifiable serum markers 
and may potentially lead to novel therapeutic strategies not only for AMD but also for other age-
associated diseases in which alternatively-activated macrophages are pathogenic. 
 
3.3 Results 
Peritoneal macrophages from old mice exhibit features of aging 
Under steady-state conditions, tissue-resident macrophages are maintained through 
constant replacement or self-renewal. In many tissues, including the peritoneal cavity, there is 
extensive replacement of macrophages as quickly as every 3 weeks (Hashimoto et al., 2013). 
Therefore, we sought to determine whether macrophages isolated from old (i.e., 18-month-old) 
wild-type mice exhibited features of cellular aging when compared to macrophages isolated from 




Mitochondrial dysfunction is a well-established hallmark of aging, and in many tissues, 
there is an age-dependent decrease in mitochondrial oxygen consumption (Lopez-Otin et al., 
2013). To determine whether peritoneal macrophages from old mice exhibit mitochondrial 
dysfunction, we measured the oxygen consumption rate (OCR) of peritoneal macrophages 
isolated from 3-month-old and 18-month-old mice. The baseline OCR of peritoneal macrophages 
from old mice was significantly lower than that of peritoneal macrophages from young mice 
(Figure 3.1A), indicating reduced basal oxidative respiration. Although both young and aged 
peritoneal macrophages appropriately exhibited a reduction in OCR after treatment with the ATP 
synthase inhibitor oligomycin, young peritoneal macrophages maintained a somewhat higher 
residual OCR (Figure 3.1A). In contrast, both young and aged peritoneal macrophages 
demonstrated similar maximal oxidative respiration in response to the uncoupling agent FCCP 
(Figure 3.1A). The difference between the baseline OCR and the OCR after oligomycin 
treatment represents ATP-linked respiration. Aged peritoneal macrophages exhibited 
significantly reduced ATP-linked respiration (Figure 3.1B), indicating mitochondrial 
dysfunction. 
Moreover, previous studies report that exposing macrophages to lipopolysaccharide 
(LPS) considerably alters their bioenergetic profile (Tavakoli et al., 2013). Furthermore, such a 
metabolic switch is required for macrophage activation and affects its subsequent inflammatory 
status (Huang et al., 2014; Tavakoli et al., 2013; Vats et al., 2006). We observed distinct 
mitochondrial respiratory profiles when comparing young and aged, LPS-treated peritoneal 
macrophages:  aged peritoneal macrophages exhibited a reduced OCR at baseline, despite 
maintaining similar responses to oligomycin and FCCP (Figure 3.1C). Again, aged peritoneal 




Cumulatively, these data demonstrate that mitochondrial oxidative metabolism is considerably 
impaired in peritoneal macrophages isolated from old mice both at baseline and in response to 
LPS. 
Furthermore, we evaluated the expression of the aging marker p16INK4a, which is a known 
senescence marker in bone marrow-derived macrophages (Randle et al., 2001) and has been 
shown to accumulate in rodent and human tissues during aging (Krishnamurthy et al., 2004; 
Nielsen et al., 1999; Zindy et al., 1997). We found that p16INK4a mRNA expression was 
significantly elevated in aged peritoneal macrophages compared to young peritoneal 
macrophages (Figure 3.1E). Collectively, these results confirm that despite their constant 
renewal, peritoneal macrophages from old mice exhibit multiple quantifiable signs of aging, 
including mitochondrial dysfunction and increased expression of the senescence marker, 
p16INK4a. 
 
Aged macrophages exhibit impaired cholesterol homeostasis 
To determine the specific cellular processes that are perturbed in aged macrophages, we 
profiled the transcriptomes of young and aged macrophages with the GeneChip Mouse Gene 1.0 
ST Array (Affymetrix, Santa Clara, CA). We found that 1,080 probe sets were significantly 
differentially expressed in aged versus young macrophages (Figure 3.2A; P < 0.05, FDR < 
0.20). The twenty protein-coding genes that were up- or downregulated with the highest fold 
change in aged versus young macrophages are presented in Table 3.1. To determine whether the 
identities of the dysregulated genes were associated with defects in particular pathways or 
cellular processes, we filtered for genes with a 1.50-fold-change cutoff (22.1%, N = 239) and 




Analytics, Philadelphia, PA). Of interest, the first, second, and tenth most significant GO 
processes implicated were sterol biosynthesis, cholesterol biosynthesis, and cholesterol 
metabolism, respectively (Figure 3.2B). Consistently, cholesterol biosynthesis was the most 
significant pathway implicated by the altered transcriptomic profile of aged macrophages 
(Figure 3.2C). As expected, the transcriptomic profile of aged macrophages also suggested 
disruptions in numerous other immune response pathways (Figure 3.2C). Overall, these results 
clearly indicate that cholesterol homeostasis is significantly perturbed during macrophage aging. 
Given that numerous genes were dysregulated in aged peritoneal macrophages, we sought 
to identify candidate transcription factors (TFs) that may regulate the aging process. Therefore, 
we performed interactome analysis to identify over-connected TFs, which may regulate the 
observed transcriptomic changes in aged macrophages. Of interest, two of the top five most 
significantly overconnected TFs were sterol regulatory element-binding protein 1 and 2 
(SREBP1/SREBP2; Figure 3.2D), which are known master regulators of cholesterol and lipid 
homeostasis. These two TFs had connectivity ratios of 14.73 and 15.15, respectively, indicating 
~15-fold overrepresentation of their known targets. These findings support our assertion that 
global lipid homeostatic mechanisms are impaired in aged macrophages. 
 To determine the specific aspects of cholesterol homeostasis that are impaired in aged 
macrophages, we analyzed the expression profile of 113 lipid-related genes in young and aged 
macrophages with a custom quantitative PCR array (Applied Biosystems). We were able to 
detect expression of 86.7% (N = 98) of the genes we tested and found that 30 of these 98 
cholesterol-related genes (30.6%) had significantly different expression in aged versus young 
macrophages (Table 3.2). When we subdivided these lipid-related genes broadly by their cellular 




cholesterol/lipid biosynthesis, elimination, transport, and uptake, among other processes. These 
findings once again confirmed that aged peritoneal macrophages exhibit global impairments in 
their ability to maintain cholesterol and lipid homeostasis. 
 
Aged macrophages have altered intracellular oxysterol content 
We previously reported that aged macrophages have higher levels of intracellular 
cholesterol related to impaired efflux (Sene et al., 2013), suggestive of the global changes in 
cholesterol homeostatic mechanisms described above. The oxidation of cholesterol to generate 
oxidized derivatives of cholesterol, or oxysterols, serves a crucial purpose to facilitate 
elimination of excess cholesterol. However, oxysterols themselves also play important signaling 
roles in regulating cholesterol homeostasis (Spann and Glass, 2013) and inflammation (Poli et 
al., 2013) and may therefore promote disease. In addition, aberrant oxysterol production can be a 
sign of increased oxidative stress, which is known to be pathogenic in AMD (Datta et al., 2017). 
Since our transcriptomic profiling demonstrated that impaired cholesterol homeostasis is a 
hallmark feature of aged macrophages, we sought to explore whether these changes were 
associated with altered oxysterol signatures, which would not only provide mechanistic insight 
into why there is impaired cholesterol homeostasis but also identify a potential approach for 
detecting defective cholesterol homeostasis. 
Using liquid chromatography tandem mass spectrometry (LC-MS/MS), we measured the 
most abundant oxysterols, including 4β-hydroxycholesterol (4β-HC), 7-ketocholesterol (7-KC), 
and cholestane-3β,5α,6β-triol (C-triol) in young and aged peritoneal macrophages. We found that 
aged peritoneal macrophages contained more 4β-HC and 7-KC compared to young peritoneal 




(Figures 3.3A and 3.3B). Aged peritoneal macrophages also had increased C-triol content at 
baseline and after treatment with oxLDL, but the difference was statistically significant only 
after treatment with 50 µg/ml oxLDL (Figure 3.3C). To account for the possibility that these 
increases in intracellular oxysterols may have been influenced by environmental factors, we also 
tested a separate cohort of young and aged mice that were housed at the same animal facility. 
Consistent with our original findings, these aged peritoneal macrophages also had increased 
levels of 4β-HC, 7-KC, and C-triol after treatment with 50 µg/ml oxLDL (data not shown). 
These findings demonstrate that aged peritoneal macrophages have increased intracellular 
oxysterols upon challenge with oxLDL and that this difference is likely an effect of age rather 
than environmental factors. 
We also measured the oxysterol content in the supernatant of peritoneal macrophages to 
determine whether increased intracellular oxysterol content was associated with increased 
oxysterol secretion. Although some comparisons were statistically significant due to low within-
group variance, the levels of 4β-HC, 7-KC, and C-triol were qualitatively similar in the 
supernatant of both young and aged peritoneal macrophages both at baseline and after treatment 
with oxLDL (Figures 3.3D, 3.3E, and 3.3F). Of note, the levels of 4β-HC and 7-KC detected in 
equivalent dilutions of oxLDL were similar to those detected in the supernatants of both young 
and aged peritoneal macrophages (Figures 3.3D and 3.3E), suggesting that any differences in 
the secretion of these two oxysterols were likely masked by the oxysterols present in the oxLDL 
itself. 
Our finding of increased intracellular oxysterols in the absence of changes in extracellular 
levels suggested that there is increased oxysterol synthesis associated with aging rather than 




macrophages have similar capacity to influx Dil-labeled oxLDL (Sene et al., 2013). Furthermore, 
using flow cytometry, we found that surface expression of CD36, a receptor for oxLDL uptake, 
was similar in young and aged peritoneal macrophages (Figures 3.3G, 3.3H, and 3.3I), 
supporting that differences in intracellular oxysterols were not likely due to differences in 
uptake. 
To determine whether these aging-associated changes in oxysterol signatures were 
specific to elicited peritoneal macrophages, we also measured intracellular oxysterol content and 
secretion in young and aged splenic macrophages as an example of a tissue-resident macrophage. 
We found that aged splenic macrophages had similar patterns of increased intracellular 
oxysterols (Figures 3.4A, 3.4B, and 3.4C) with minimal changes in extracellular oxysterols 
(Figures 3.4D, 3.4E, and 3.4F). These findings indicate that impaired cholesterol homeostasis is 
associated with detectable alterations in the oxysterol signatures in aged macrophages of multiple 
origins. 
 
PBMC and plasma oxysterol signatures are altered with age in humans 
We have previously demonstrated that aged murine macrophages exhibit functional shifts 
that are associated with their tendency to promote AMD (Apte et al., 2006; Nakamura et al., 
2015; Sene et al., 2013). However, it remains unclear which subset of the age-associated changes 
described above promotes disease rather than being a part of physiologic aging. To discriminate 
between these physiologic versus pathologic changes, we assessed whether PBMCs and plasma 
samples from healthy human subjects also exhibited changes in oxysterol signatures with age 




samples minimally without cell sorting or cultures to explore how these oxysterol signatures 
could be used clinically. Demographic information of the human subjects is shown in Table 3.3. 
In addition to measuring the same oxysterols we measured in murine peritoneal 
macrophages (i.e., 4β-HC, 7-KC, and C-triol), we were also able to quantify levels of two 
additional enzymatically generated oxysterols, 24-hydroxycholesterol (24-HC) and 27-
hydroxycholesterol (27-HC), which were below the limit of detection in the murine samples. Of 
interest, we observed a statistically significant negative correlation between age and PBMC 7-
KC levels (Figure 3.5A; Spearman R = -0.2964, P = 0.0204), PBMC C-triol levels (Figure 
3.5A; Pearson R = -0.3068, P = 0.0171), and PBMC 24-HC levels (Figure 3.5B; Pearson R = -
0.3058, P = 0.0165). There was no association between age and PBMC 4β-HC levels (Figure 
3.5A; Spearman R = -0.0356, P = 0.7853) or PBMC 27-HC levels (Figure 3.5B; Pearson R = -
0.0012, P = 0.9930). Additionally, we observed a significant positive correlation between age 
and plasma C-triol levels (Figure 3.5C; Pearson R = 0.2818, P = 0.0278). Although not 
statistically significant, there was a trend (0.05 < P < 0.10) toward a positive correlation between 
age and plasma 4β-HC levels (Figure 3.5C; Spearman R = 0.2170, P = 0.0930). There was no 
statistically significant correlation between age and plasma 7-KC levels (Figure 3.5C; Spearman 
R = 0.1172, P = 0.3683), plasma 24-HC levels (Figure 3.5D; Spearman R = 0.0394, P = 0.7631), 
or plasma 27-HC levels (Figure 3.5D; Pearson R = 0.1601, P = 0.2177). Overall, these findings 
suggest that healthy humans also exhibit age-associated alterations in oxysterol signatures, likely 







Plasma 24-hydroxycholesterol distinguishes AMD from physiologic aging 
To further characterize the relationship between age-associated oxysterol signatures and 
age-related disease, we recruited human patients with early or advanced neovascular (wet) AMD 
and measured their PBMC and plasma oxysterol levels (Figures 3.6A, 3.6B, 3.6C, 3.6D, 3.6E, 
3.6F, 3.6G, 3.6H, 3.6I, and 3.6J). While AMD patients were significantly older than non-AMD 
control subjects, there was no difference between the groups on the basis of gender (Table 3.3). 
On average, AMD patients had decreased PBMC 7-KC levels compared to non-AMD controls 
(Figure 3.6B) but no differences in the other PBMC oxysterol levels (Figures 3.6A, 3.6C, 3.6D, 
and 3.6E). Moreover, AMD patients had elevated plasma 4β-HC levels (Figure 3.6F), elevated 
plasma C-triol levels (Figure 3.6H), elevated plasma 24-HC levels (Figure 3.6I), and a trend 
(0.05 < P < 0.10) towards elevated plasma 27-HC levels (Figure 3.6J) compared to non-AMD 
controls. There was no difference in plasma 7-KC levels (Figure 3.6G). 
Given the known association between AMD and age and the significant age difference 
between our two groups, we performed binary logistic regression to precisely model the 
relationship between PBMC or plasma oxysterol levels and AMD after controlling for age and 
gender (Table 3.4). We selected PBMC 7-KC, plasma 4β-HC, plasma C-triol, and plasma 24-
HC levels as candidates for further analysis since these were the oxysterols that were 
significantly different between AMD patients and controls. The binary logistic regression model 
for a PBMC oxysterol AMD signature included age, gender, and untransformed PBMC 7-KC. 
The overall model was statistically significant (LR Χ2 = 34.0, df = 3, P < 0.001) and had good fit 
(Χ2 = 9.6, df = 8, P = 0.294). As expected, age was significantly associated with AMD (P < 




with increased odds of having AMD (aOR = 1.10; 95% CI = 1.05 to 1.16). However, after 
controlling for age and gender, PBMC 7-KC levels were not associated with AMD (P = 0.140). 
The binary logistic regression model for a plasma oxysterol AMD signature included 
forced entry of age and gender and selection of any combination of the candidate plasma 
oxysterol species through automated forward selection (Table 3.5). The final model was 
statistically significant (LR Χ2 = 44.9, df = 3, P < 0.001), had good fit (Χ2 = 14.2, df = 8, P = 
0.078), and included age, gender, and plasma 24-HC levels. As expected, age was significantly 
associated with AMD (P < 0.001) with a beta coefficient of 0.107, indicating that each additional 
year of age was associated with increased odds of having AMD (aOR = 1.113; 95% CI = 1.06 to 
1.17). Of significant interest, even after controlling for age and gender, 24-HC levels were highly 
associated with AMD (P < 0.001) with a beta coefficient of 11.327, indicating that each 
additional 0.1-unit increase in relative plasma 24-HC levels was associated with a 3.10-fold 
increase in odds of having AMD (95% CI = 1.66 to 5.79). To determine the efficacy of plasma 
24-HC levels as a potential marker for AMD, we generated a receiver operating characteristic 
(ROC) curve and found that the area under the ROC curve (AUC) was 0.866 (95% CI = 0.793 to 
0.939), indicating good discrimination. 
Furthermore, we performed conjunctive analysis to evaluate the clinical utility of using 
plasma 24-HC to discriminate between AMD patients and non-AMD subjects across varying 
ages. We divided patients into tertiles by plasma 24-HC levels and by age (i.e., above versus 
below median), tabulating the AMD prevalence in each conjoined cell (Table 3.6). This analysis 
demonstrated a clear stepwise increase in prevalence of AMD in subjects above the median age 
going from the lowest to the highest tertile of plasma 24-HC (i.e., from 47.1% to 66.7% to 




median age based on plasma 24-HC tertile (i.e., from 10.5% to 19.0% to 38.5%). These findings 
support the notion that plasma 24-HC levels can distinguish between the changes in oxysterols 
expected during physiologic aging versus those that suggest risk of AMD. 
To determine the clinical utility of plasma 24-HC levels compared to existing clinical 
measures of lipid homeostasis, we next analyzed whether plasma 24-HC levels were correlated 
with total plasma cholesterol levels in the subjects for whom this information was available. In 
these subjects (N = 37), plasma 24-HC was indeed correlated with total plasma cholesterol (r = 
.659, P < 0.001). We therefore performed a subanalysis by generating a binary logistic regression 
for the outcome of AMD with forced entry of plasma 24-HC levels, total plasma cholesterol, age, 
and gender. This model was statistically significant (LR Χ2 = 27.2, df = 4, P < 0.001) and had 
good fit (Χ2 = 2.6, df = 7, P = 0.921). Of interest, total plasma cholesterol levels were not 
associated with AMD (aOR = 1.014; 95% CI = 0.97 to 1.06; P = 0.547). Remarkably, even after 
controlling for total plasma cholesterol, age, and gender, plasma 24-HC remained highly 
associated with AMD (P = 0.044) with a beta coefficient of 19.308, indicating that each 
additional 0.1-unit increase in relative plasma 24-HC levels was associated with a 6.90-fold 
increase in odds of having AMD (95% CI = 1.05 to 45.09). Despite the limited sample size 
available for this subanalysis, these findings suggest that human plasma 24-HC has strong 
diagnostic value compared to the existing measure of total plasma cholesterol. 
Given the heterogeneity of the clinical progression of AMD and our interest in 
identifying factors that may predict transition to advanced disease, we also examined whether 
plasma 24-HC levels differed significantly when subdividing AMD patients into early AMD and 
advanced neovascular AMD patients. We did not detect a statistically significant difference in 




Therefore, although 24-HC may be associated with AMD, it does not appear to have utility for 
predicting disease progression. 
 
3.4 Discussion 
In this study, we identified that despite their self-renewal, macrophages from old mice 
exhibit signs of aging, such as defects in mitochondrial oxidative respiration, that are not 
observed in macrophages from young mice. Consistent with these functional changes, aged 
macrophages exhibit an altered transcriptomic profile, especially in genes involved in cholesterol 
homeostasis. These findings build on our previous study reporting that Abca1 expression is 
significantly reduced in aged macrophages, leading to impaired cholesterol efflux (Sene et al., 
2013). We further demonstrate that impairments in cholesterol homeostatic mechanisms are not 
restricted solely to efflux but globally affect numerous pathways, including biosynthesis, 
elimination, transport, and regulation. Interestingly, aged macrophages exhibited simultaneous 
downregulation and upregulation of different genes with similar functions in cholesterol-related 
pathways (Table 3.2), indicating broad and complex dysregulation of cholesterol homeostasis. 
Our hypothesis that impaired cholesterol metabolism in aged macrophages contributes to 
AMD pathogenesis is consistent with numerous epidemiological studies that have established 
that parameters related to lipid status, such as baseline high-density lipoprotein-cholesterol 
(HDL-C) and total serum cholesterol, affect risk of AMD development and progression (Burgess 
and Davey Smith, 2017; Tomany et al., 2004; Yip et al., 2015). Moreover, one past genome-wide 
association study reported that polymorphisms in lipid-related genes such as LIPC, ABCA1, and 
CETP are associated with advanced AMD (Neale et al., 2010). These findings have led to the 




the development or progression of AMD (Hall et al., 2001). The findings of one non-randomized 
study suggest that high-dose statins may indeed reduce some high-risk features of AMD (Vavvas 
et al., 2016), although large randomized studies are necessary to confirm these findings (Apte, 
2016) given that numerous other studies report conflicting results (Gehlbach et al., 2016). 
Cumulatively, these conflicting findings highlight that the relationship between aging, impaired 
cholesterol homeostasis, and AMD is complex and warrants further investigation. 
In this study, we found that in aged murine macrophages, a transcriptomic profile 
suggesting impaired cholesterol homeostasis was associated with aberrant intracellular oxysterol 
levels, especially when the macrophages were treated with oxLDL. In many immune cells, 
oxysterols can directly regulate liver X receptor (LXR) transcriptional activity, which can 
modulate cellular lipid metabolism and the immune response, especially in inflammation-
associated diseases (Spann and Glass, 2013). For example, 27-HC, the most prevalent oxysterol 
in atherosclerotic lesions, has been shown to promote atherosclerosis by inducing inflammation 
(Umetani et al., 2014). Therefore, in addition to being a surrogate marker for impaired 
cholesterol homeostasis, altered oxysterol production may itself play a pathogenic role in 
promoting cholesterol dysregulation. We found that, similar to murine macrophages, human 
PBMC and plasma samples also demonstrated age-dependent changes in oxysterols. Although 
the directionality of these age- and disease-associated changes did not correspond perfectly, our 
data suggest that broad dysregulation of cholesterol homeostasis in both aging and disease is 
associated with altered oxysterol signatures. 
These findings build on recent reports that monocytes isolated from patients with 
neovascular AMD exhibit an altered immune-related transcriptomic signature (Grunin et al., 




characteristics that may contribute to disease pathogenesis (Hagbi-Levi et al., 2017). Past studies 
have also shown that in the outer retina, accumulation of cholesterol oxidation products such as 
7-KC can disrupt the immune environment and transform resident macrophages into disease-
promoting cells (Indaram et al., 2015). Specifically, uptake of 7-KC in microglial cells results in 
decreased production of neurotrophic growth factors and increased expression of angiogenic 
mediators that promote pathologic CNV (Indaram et al., 2015). 
How to distinguish whether changes in oxysterol signatures define aging, disease, or both 
is of great interest, as defects in lipid metabolism are a shared feature of multiple diseases. As an 
example, certain oxysterols and their metabolites have been shown to be specific biomarkers for 
Niemann-Pick type C (NPC) disease, an inherited lysosomal storage disease (Jiang et al., 2016; 
Porter et al., 2010). In this study, we found that after controlling for age and gender, plasma 24-
HC was significantly associated with AMD. Despite our modest sample size (N = 107), these 
findings suggest that 24-HC is a strong candidate for an oxysterol that distinguishes AMD from 
physiologic aging. Our subanalysis revealed that plasma 24-HC remained highly associated with 
AMD even after controlling for total plasma cholesterol, highlighting its diagnostic value. Larger 
prospective studies are necessary to validate these findings and identify additional markers of 
risk. 
Cumulatively, our findings highlight that impaired cholesterol homeostasis is a key 
pathway perturbed in aged macrophages and that oxysterol signatures in patient samples can 
distinguish AMD from physiologic aging. Ultimately, these findings may not only improve our 
ability to diagnose disease but also identify novel targets in cholesterol homeostasis that may be 







Animals. All animal experiments were approved by the Institutional Animal Care and Use 
Committee (IACUC) and performed in accordance with the Washington University School of 
Medicine Animal Care and Use guidelines. We obtained old (i.e., ~18-month-old), female wild-
type C57BL/6J mice from the National Institute on Aging (Bethesda, MD) and compared them 
to strain-matched young (i.e., ~3-month-old), female wild-type C57BL/6J controls. We 
harvested peritoneal macrophages five days after elicitation with a 2-ml intraperitoneal injection 
of 4% thioglycollate broth (Sigma-Aldrich, St. Louis, MO). We harvested splenic macrophages 
by performing positive magnetic cell separation with the PE selection kit (Stem Cell 
Technologies) and PE anti-F4/80 monoclonal antibody (clone: BM8; eBioscience, Waltham, 
MA), following manufacturer’s instructions. We cultured peritoneal and splenic macrophages in 
GibcoTM RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA) supplemented with 
10% fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, GA) and 1% penicillin-
streptomycin (Thermo Fisher Scientific). When indicated, we treated macrophages with 25 or 50 
µg/ml of oxidized LDL (oxLDL; Alfa Aesar, Haverhill, MA) for 24 hours prior to further 
analysis. 
 
OCR measurements. To perform metabolic characterization, we measured the oxygen 
consumption rate (OCR) of peritoneal macrophages as a surrogate marker for oxidative 
respiration with the XF96 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, 




(Seahorse Bioscience) at 100,000 cells per well. On the morning of the experiment, we washed 
the cells and replaced the media with Seahorse assay media (Seahorse Bioscience) supplemented 
with 25 mM glucose (Sigma-Aldrich, St. Louis, MO) and 1 mM sodium pyruvate (Thermo 
Fisher Scientific) and adjusted the pH to 7.4. After incubation in a non-CO2 incubator at 37°C 
for 1 hour, we measured OCR at baseline and after sequential treatment with the following 
chemicals from the Mito Stress Test Kit (Seahorse Bioscience): 3 µM oligomycin, 5 µM 
carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), and 1 µM rotenone/antimycin 
A (rot/AA). Each cycle consisted of 2 minutes of mixing and a 1-minute pause, followed by a 5-
minute measurement period; we repeated each cycle 3-4 times. We normalized the background 
for all measurements by subtracting the average OCR of each sample after treatment with 
rot/AA. 
 
Gene expression analysis. We extracted total RNA from peritoneal macrophages with the 
RNeasy Mini Kit (Qiagen) and prepared cDNA with the High-Capacity Reverse Transcription 
Kit (Applied Biosystems), following manufacturer’s instructions. We performed quantitative 
PCR amplification of cDNA using either the TaqMan® probe-based gene expression assay for 
p16INK4a (Mm00494449_m1; Applied Biosystems) or custom TaqMan® Array Plates (Applied 
Biosystems) for lipid-related genes. In all cases, we used the ΔΔCT method, normalizing to Actb, 
18sRNA, Gapdh, or the geometric mean of a combination of these endogenous controls. 
 
Transcriptome expression profiling. We isolated total RNA from peritoneal macrophages with 




(NuGEN, San Carlos, CA), and performed target labeling with the Encore® Biotin Kit 
(NuGEN), according to manufacturer's instructions. We then performed whole transcriptome 
profiling of young and aged peritoneal macrophages using Mouse Gene (MoGene) 1.0 ST arrays 
processed with Affymetrix Expression Console (v1.3.1.187) at standard settings (RMA 
background correction, median polish summarization, and quantile normalization) to generate 
intensity values. We assigned each probeset of the MoGene 1.0 array a detection call of ‘mean + 
2×SD’ of the negative controls. We performed data quality control to identify potential outliers 
by principal component analysis (PCA) plot and hierarchical clustering, as well as by quality 
control (QC) metrics (all probeset RLE means > 0.25) in Expression Console. From this QC, we 
omitted one sample in the young peritoneal group. We then filtered data by probeset type 
(“main” in MoGene 1.0) and by detection call (any probesets without a ‘detected’ call in any of 
the samples were removed). Any probeset without a gene symbol in the MoGene 1.0 data was 
also removed. 18,066 MoGene 1.0 probesets (from the total of 35,556) were kept for further 
analysis. We analyzed the data using the R package “limma” and generated gene lists based on 
P-values and false detection rate (FDR) q-values. We performed gene ontology (GO), pathway 
map, and interactome analyses with MetaCoreTM (Clarivate Analytics, Philadelphia, PA). 
 
Flow cytometry. We plated peritoneal macrophages on untreated Petri dishes and allowed them 
to adhere overnight. The next morning, we lifted cells by incubating for 5 minutes in ice-cold 
Dulbecco’s phosphate-buffered saline (DPBS; Thermo Fisher Scientific) without calcium or 
magnesium and scraping gently. We next filtered cells through a 40 µm cell strainer, washed 
them with DPBS, and resuspended them in DPBS containing 5% FBS, 10 mM HEPES, 1 mM 




with APC anti-mouse CD36 (clone: HM36; BioLegend), PE/Cy7 anti-mouse CD64 (clone: X54-
5/7.1; BioLegend), and PE anti-mouse F4/80 (clone: BM8; eBioscience) antibodies for 20 
minutes on ice. We then washed and resuspended cells in DPBS and acquired data on a BD X-20 
or BD LSR II flow cytometer (BD Biosciences, San Jose, CA). We analyzed and visualized data 
with FlowJo v10. 
 
Human subjects. This study was approved by the Human Research Protection Office of 
Washington University School of Medicine and adhered to the Declaration of Helsinki. We 
obtained informed consent from all subjects prior to blood collection. To purify peripheral blood 
mononuclear cells (PBMCs) and plasma, we performed density gradient centrifugation with BD 
Vacutainer CPTTM Cell Preparation Tubes (Franklin Lakes, NJ), following manufacturer’s 
instructions. We classified patients as no AMD, early AMD, or wet AMD based on established 
clinical criteria (Ferris et al., 2005). Early AMD patients had either moderate drusen (>63 µm) or 
pigment changes in at least one eye but no CNV or GA in either eye at the time of sample 
collection. Wet AMD patients had CNV in at least one eye at the time of sample collection. We 
stored all samples at -80°C until further analysis. To determine the appropriate sample size, we 
performed an a priori power analysis with G*Power 3.1 (Faul et al., 2007). Estimating an effect 
size d of 0.6 based on pilot experiments, we calculated that we needed 94 subjects with an 
allocation ratio of 1.5:1 to detect a significant difference between the groups at the two-sided α = 
0.05 level with 80% power. For the subanalysis, we performed chart review to identify the 






Oxysterol profiling by LC-MS/MS. We extracted and quantified oxysterol levels from murine 
peritoneal macrophage pellets, the supernatant of murine peritoneal macrophages, human PBMC 
cell pellets, and human plasma samples as previously described (Jiang et al., 2011). Briefly, we 
added deuterated oxysterols to the samples as internal standards and then extracted oxysterols 
with methanol. We derivatized the extracted oxysterols and their internal standards with N,N-
dimethylglycinate (DMG) to increase MS sensitivity. We performed oxysterol analysis with a 
Shimadzu 20AD HPLC system (Kyoto, Japan) and a LeapPAL autosampler coupled to a tandem 
mass spectrometer (API 4000; Applied Biosystems) operated in MRM mode. We used positive 
ion ESI mode for detection of the derivatized oxysterols, injecting study samples in duplicate for 
data averaging. We conducted data processing with Analyst 1.5.1 (Applied Biosystems) and 
determined relative levels of each oxysterol by comparing its measurement with that of its 
corresponding deuterated internal standard. We normalized the murine macrophage oxysterol 
levels to cell number, murine supernatant levels to volume, human PBMC oxysterol levels to 
protein content, and human plasma oxysterol levels to volume. To normalize human samples 
processed on different days, we used one of the patient samples as an internal control. 
 
Statistics. We performed statistical analysis as indicated in the figure legends with Prism 5 
(GraphPad Software) or SPSS Statistics Version 23 (IBM, Armonk, NY). We assessed the 
normality of our data graphically and with the Kolmogorov-Smirnov test and used appropriate 
non-parametric alternatives when necessary. We considered P < 0.05 to be statistically 
significant. To model the relationship between PBMC and plasma oxysterol signatures and 
AMD, we generated binary logistic regression models. Our model included the following 




levels. For the subanalysis, we generated an additional binary logistic regression model, which 
included the following predictor variables: age at time of sample collection, gender, plasma 24-
HC levels, and total plasma cholesterol. For all regression models, we assessed fit with the 
Hosmer-Lemeshow lack-of-fit test and performed diagnostics by examining Cook’s distances, 
leverages, and residual deviances. The final reported models had six omitted cases based on 
sensitivity analysis. We checked for problems with collinearity by examining variance inflation 
factors (VIF). We used an unadjusted α of 0.05 for the binary logistic regression. 
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Figure 3.1. Peritoneal macrophages from old mice exhibit quantifiable signs of aging. (A) Aged peritoneal 
macrophages had reduced oxygen consumption rate (OCR) both at baseline (N = 9/group; 2-tailed, unpaired 
Welch’s t-test) and in response to oligomycin (N = 11-12/group; 2-tailed, unpaired t-test) and significantly reduced 
ATP-linked respiration (B; N = 9/group; 2-tailed, unpaired Welch’s t-test). (C) Lipopolysaccharide (LPS)-treated 
aged peritoneal macrophages also had impaired mitochondrial bioenergetics at baseline (N = 8-12/group; 2-tailed, 
unpaired Welch’s t-test) and significantly reduced ATP-linked respiration (D; N = 6-9/group; 2-tailed, unpaired t-
test) compared to LPS-treated young peritoneal macrophages. (E) Aged peritoneal macrophages had increased 
mRNA expression of the senescence marker p16INK4a (N = 10/group; 2-tailed, unpaired t-test). Open circles depict 








Figure 3.2. Transcriptomic profiling of aged peritoneal macrophages. (A) Aged peritoneal macrophages display 
numerous transcriptomic changes, which suggest perturbations in various gene ontology (GO) processes (B) and 
pathway maps (C). (D) Interactome analysis revealed numerous overconnected transcription factors (TFs) whose 








Figure 3.3. Aged peritoneal macrophages have abnormal oxysterol content. (A-C) Aged peritoneal macrophages 
contained significantly more intracellular 4β-hydroxycholesterol (4β-HC) and 7-ketocholesterol (7-KC) than their 
young counterparts at baseline and after treatment with 25 or 50 µg/ml oxidized LDL (oxLDL) (N = 5/group; 2-way 
ANOVA) and significantly more intracellular cholestane-3β,5α,6β-triol (C-triol) after treatment with 50 µg/ml 
oxLDL (N = 5/group; 2-way ANOVA with Bonferroni post-hoc test). (D-F) Although some comparisons were 
statistically significant due to low within-group variance, the supernatant of young and aged peritoneal macrophages 
contained qualitatively similar levels of 4β-HC, 7-KC, and C-triol both at baseline and after treatment with oxLDL 
(N = 5/group; 2-way ANOVA with Bonferroni post-hoc test). (G) Representative flow cytometry plot from young 
and aged peritoneal macrophages showing gating on macrophage markers CD64 and F4/80. (H-I) Young and aged 
peritoneal macrophages exhibited similar CD36 surface expression. Isotype staining (iso) was identical between 
groups (N = 5/group; 2-tailed, unpaired t-test). Open circles depict individual data points; horizontal lines depict 





Figure 3.4. Aged splenic macrophages (SM) have abnormal oxysterol content. (A-C) Aged SM contained 
significantly more intracellular 4β-hydroxycholesterol (4β-HC), 7-ketocholesterol (7-KC), and cholestane-3β,5α,6β-
triol (C-triol) compared to their young counterparts after treatment with 50 µg/ml oxidized LDL (oxLDL) (N = 
3/group; 1-tailed Mann-Whitney U test). (D-F) The supernatant of young and aged SM contained similar levels of 
4β-HC, 7-KC, and C-triol both at baseline and after treatment with oxLDL (N = 3/group; 2-tailed Mann-Whitney U 





Figure 3.5. Age affects human peripheral blood mononuclear cell (PBMC) and plasma oxysterol signatures. (A-B) 
There was a significant negative correlation between age and PBMC 7-KC levels, PBMC C-triol levels, and PBMC 
24-HC levels in healthy human subjects. (C-D) There was a significant positive correlation between age and plasma 
C-triol levels and a trend towards a positive correlation between age and plasma 4β-HC levels. Open circles depict 
individual data points; lines depict the best-fitting linear regression line (A-D; r = Pearson product-moment 







Figure 3.6. Age-related macular degeneration (AMD) patients have altered peripheral blood mononuclear cell 
(PBMC) and plasma oxysterol signatures. (A-J) We measured PBMC and plasma levels of 4β-HC, 7-KC, C-triol, 
24-HC, and 27-HC. AMD patients (N = 44-45) had decreased PBMC 7-KC levels (B; 2-tailed Mann-Whitney U 
test), elevated plasma 4β-HC levels (F; 2-tailed Mann-Whitney U test), elevated plasma C-triol levels (H; 2-tailed 
Mann-Whitney U test), elevated plasma 24-HC levels (I; 2-tailed Mann-Whitney U test), and a trend towards 
elevated plasma 27-HC levels (J; 2-tailed, unpaired t-test) compared to non-AMD controls (N = 61). Open circles 
depict individual data points; horizontal lines depict mean ± 95% confidence intervals (A-J) (* P < 0.05; ** P < 





Figure 3.7. Plasma 24-HC levels discriminate age-related macular degeneration (AMD) from physiologic aging. (A) 
We divided patients into tertiles by plasma 24-HC and by age (i.e., above versus below median age) and found that 
individuals in the highest tertile of plasma 24-HC who were also above median age (top right) had the highest AMD 
prevalence. Horizontal dashed grey lines demarcate plasma 24-HC tertiles; the vertical dashed grey line indicates the 
median age. (B) We did not observe a statistically significant difference in plasma 24-HC levels in early AMD 
patients versus advanced neovascular (wet) AMD patients (N = 21 early AMD; 24 wet AMD; 2-tailed, unpaired t-








Table 3.1. Top ten up- and down-regulated genes in aged versus young peritoneal macrophages. 
Probeset ID Gene symbol Fold changea  P-value FDR 
10463355 Scd2 -3.645 .0007 .0667 
10506571 Dhcr24 -2.522 .0001 .0361 
10347748 Acsl3 -2.406 .0003 .0497 
10560702 Ceacam19 -2.266 <.0001 .0307 
10403413 Idi1 -2.070 .0018 .0952 
10544273 Clec5a -1.996 .0006 .0634 
10482762 Idi1 -1.977 .0021 .1006 
10420668 Mir15a -1.969 .0016 .0924 
10424349 Sqle -1.969 <.0001 .0115 
10527920 Cyp51 -1.967 .0012 .0851 
     
10582879 Csprs  3.771 <.0001 .0258 
10538126 Gimap4  4.368 .0052 .1382 
10551025 Cd79a  6.435 .0018 .0957 
10429520 Ly6d  6.483 .0028 .1104 
10466172 Ms4a1  7.480 .0025 .1050 
10392142 Cd79b  7.764 .0004 .0552 
10458278 Mzb1 9.573 .0002 .0469 
10523359 Cxcl13  11.166 .0015 .0918 
10531724 Plac8  11.549 .0006 .0634 
10429564 Ly6a  12.571 <.0001 .0306 
aAged versus young peritoneal macrophages (negative fold-change reflects 





Table 3.2. Expression profiling of lipid-related genes in aged and young macrophages. 
Cellular function Gene symbol Fold changea  P-valueb 
Biosynthesis Fads2 -1.545 .050 
 Fads3 1.299 .050 
 Fdft1 -3.831 .050 
 Fdps -1.885 .050 
 Hmgcs2 3.122 .050 
 Prkaa2 2.773 .046 
 Scd1 -1.895 .050 
Elimination Cyp11a1 -9.342 .050 
 Cyp7b1 2.515 .046 
 Cyp27a1 -1.473 .050 
 Hadhb -1.984 .050 
 Lpl 1.496 .050 
 Tbxas1 1.249 .050 
Leukotriene signaling Lta4h -1.314 .050 
 Alox5ap -1.919 .050 
Transport Apoa1 -6.985 .046 
 Apof -6.089 .050 
 Slc16a6 -1.459 .050 
 Slc27a1 -1.659 .050 
 Slc27a3 -4.402 .050 
 Stard4 -1.306 .050 
Uptake Cxcl16 -1.927 .050 
 Olr1 -2.340 .050 
 Pcsk9 -1.903 .050 
 Stab2 -3.008 .046 
Other or multiple functions Adfp 2.102 .050 
 Alox15 5.797 .050 
 Fabp4 1.338 .050 
 Nr0b2 -3.911 .037 
 Nr1h3 -1.561 .050 
aAged versus young peritoneal macrophages (negative fold-change reflects 
decreased expression in aged macrophages relative to young macrophages); 




Table 3.3. Demographic and clinical characteristics of human subjects. 
Demographic parameter Control AMD P-value 
Age, median (range) 64.09 (21.59-87.07) 74.11 (47.87-100.50) <.0001a 
Sex, N    
     Male 37 23 .3781b 
     Female 25 22  
AMD status, N    
     No AMD 62 0 N/A 
     Early AMD 0 21  
     Advanced neovascular AMD 0 24  







Table 3.4. Beta coefficients from PBMC binary logistic regression model. 
Predictor variable aOR (eβ) 95% CI of eβ P-value 
Age 1.103 1.049 to 1.161 <.001 
Female gender .893 .335 to 2.381 .821 







Table 3.5. Beta coefficients from plasma binary logistic regression model. 
Predictor variable aOR (eβ) 95% CI of eβ P-value 
Age 1.113 1.055 to 1.174 <.001 
Female gender .390 .119 to 1.282 .121 







Table 3.6. AMD as a function of age and plasma 24-HC levels. 
  Age 
  Below median Above median Total 
Plasma 
24-HC 
Lowest tertile 2/19 (10.5%) 8/17 (47.1%) 10/36 (27.8%) 
Middle tertile 4/21 (19.0%) 10/15 (66.7%) 14/36 (38.9%) 
Highest tertile 5/13 (38.5%) 16/21 (76.2%) 21/34 (61.8%) 
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Macrophage aging is pathogenic in diseases of the elderly, including age-related macular 
degeneration (AMD), a leading cause of blindness in older adults. However, the role of 
microRNAs, which modulate immune processes, in regulating macrophage dysfunction and 
thereby promoting age-associated diseases is underexplored. Here, we report that microRNA-150 
coordinates transcriptomic changes in aged murine macrophages, especially those associated 
with aberrant lipid trafficking and metabolism in AMD pathogenesis. Molecular profiling 
confirmed that aged murine macrophages exhibit dysregulated ceramide and phospholipid 
profiles compared to young macrophages. Of translational relevance, upregulation of 
microRNA-150 in human peripheral blood mononuclear cells was also significantly associated 
with increased odds of AMD, even after controlling for age. Mechanistically, microRNA-150 
directly targets stearoyl-CoA desaturase-2, which coordinates macrophage-mediated 
inflammation and pathologic angiogenesis, as seen in AMD, in a vascular endothelial growth 
factor (VEGF)-independent manner. Together, our results implicate microRNA-150 as 





Macrophages are critical effector cells of the innate immune system. Multiple groups, 
including our own, have reported that macrophages from aged mice demonstrate a functional 
drift compared to those isolated from young mice. For example, aged macrophages exhibit 
epigenomic changes, leading to reduced autophagic capacity (Khalil et al., 2016), and are 
defective in their ability to fight viral infections due to reduced phagocytic activity (Wong et al., 
2017). Moreover, aged macrophages are skewed towards a proangiogenic gene and cytokine 
expression profile, which leads to dysregulated inflammation and inability to inhibit pathological 
angiogenesis (Kelly et al., 2007). Aged macrophages also exhibit impaired cholesterol efflux due 
to decreased Abca1 expression, leading to intracellular cholesterol accumulation and pathologic 
vascular proliferation (Sene et al., 2013). Age-associated macrophage dysfunction has been 
proposed to contribute to the pathogenesis of numerous diseases of aging, including age-related 
macular degeneration (AMD) and atherosclerosis (Sene and Apte, 2014). In addition, age-
associated changes in microglia, the major resident immune cell in the retina with similar 
phagocytic functions, may also promote AMD (Ma and Wong, 2016). 
AMD is a leading cause of blindness in industrialized nations (van Leeuwen et al., 2003) 
and displays a complex disease course characterized, initially, by accumulation of cholesterol-
rich deposits known as drusen underneath the retina (Sene and Apte, 2014; Sene et al., 2015). 
Though drusen themselves do not typically cause vision loss, they are a risk factor for 
progression to one of two forms of advanced AMD: advanced neovascular (wet) AMD, 
characterized by pathologic subretinal angiogenesis, or advanced dry AMD, characterized by 
geographic atrophy secondary to loss of retinal neurons and underlying cells. Both forms of 




significant portion of the vision loss associated with AMD (Ferris et al., 1984). While anti-
vascular endothelial growth factor (VEGF) therapies have revolutionized treatment options for 
wet AMD, an important subset of patients is un- or under-responsive to these therapies (Sene et 
al., 2015). Of interest, genome-wide association studies show that polymorphisms in lipid-related 
genes, including hepatic lipase (LIPC), ATP-binding cassette transporter member 1 (ABCA1), 
and cholesterol ester transfer protein (CETP), are associated with advanced AMD (Neale et al., 
2010), supporting the idea that impaired cholesterol homeostasis contributes to AMD 
pathogenesis. 
Impaired cholesterol homeostasis also contributes to the pathogenesis of atherosclerosis. 
Atherosclerotic plaque formation begins when circulating monocytes adhere to the vascular 
endothelium, migrate to the sub-endothelial space, and differentiate into macrophages that take 
up lipids and become foam cells (Gerrity, 1981; Gerrity et al., 1979). Past studies have 
demonstrated that the activation/polarization state of macrophages is important for predicting 
plaque phenotype and stability (Chinetti-Gbaguidi et al., 2015; Peled and Fisher, 2014). For 
example, in patients with hypercholesterolemia, macrophages polarize to a more 
proinflammatory state, which could predispose to plaque formation (Fadini et al., 2014). 
Moreover, macrophage cholesterol efflux capacity in human patients is a clinically relevant 
predictor of atherosclerotic coronary artery disease (Ishikawa et al., 2015), suggesting that 
perturbations in cholesterol homeostasis promote disease. Remarkably, atherosclerotic plaques 
and drusen have similar lipid compositions (Crabb et al., 2002; Curcio et al., 2009; Kramsch et 
al., 1971; Mullins et al., 2000), unifying the pathogenic pathways underlying these diseases. 




lipid-lowering drugs used to treat atherosclerosis, for treating AMD (Apte, 2016; Vavvas et al., 
2016), although not all studies have yielded the same conclusions (Gehlbach et al., 2016). 
Despite these advances in our understanding of the phenotype of aged macrophages and 
how such changes contribute to age-associated diseases, the molecular mechanisms by which 
macrophages drift towards the disease-promoting phenotype remain poorly understood. Given 
the immense spectrum of these changes in aged macrophages, we hypothesized that microRNAs 
(miRs) may regulate the transcriptome of macrophages and thereby the transition of 
macrophages to a disease-promoting phenotype. The ability of miRs to target multiple genes 
makes them strong candidates as molecular regulators that skew macrophages towards a disease-
promoting phenotype. Previous studies have examined the miR signatures of AMD by profiling 
eye fluids, such as human vitreous humor and plasma, providing phenotypic characterization, but 
have failed to provide mechanistic insights into the underlying disease etiology (Grassmann et 
al., 2014; Menard et al., 2016). Therefore, further elucidation of the target genes of these miRs, 
the affected cell types, and the molecular pathways involved is necessary for a more complete 
understanding of disease pathogenesis. 
In this study, we sought to identify one or more miR(s) that regulate the disease-
promoting programmatic changes in macrophages that are associated with AMD. Our results 
demonstrate that miR-150 is highly upregulated both in disease-promoting murine macrophages 
and in human peripheral blood mononuclear cells from AMD patients. Moreover, we show that 
miR-150 regulates macrophage-mediated inflammation and pathologic angiogenesis 
independently from vascular endothelial growth factor (VEGF) by targeting stearoyl-CoA 
desaturase-2 (Scd2), suggesting that it regulates the transition of macrophages from a healthy 




mechanisms underlying the pathological programmatic changes in aged macrophages and may 
lead to the identification of novel therapeutic targets and candidate biomarkers. 
 
4.3 Results 
Aged macrophages have distinct cholesterol-responsive microRNA networks 
 Since miRs can regulate numerous target genes, we hypothesized that miRs may globally 
regulate the macrophage’s response to exogenous cholesterol. We first sought to identify 
cholesterol-responsive miRs by performing a microarray, comparing untreated macrophages 
versus macrophages treated with acetylated LDL (acLDL) or oxidized LDL (oxLDL). We 
previously showed that aged and young macrophages handle cholesterol differently and that aged 
macrophages demonstrate altered capacity to metabolize cholesterol (Sene et al., 2013). As such, 
we profiled aged and young macrophages separately to accurately capture the response of these 
cells to exogenous cholesterol. In young macrophages, ten miRs were similarly downregulated in 
response to both acLDL and oxLDL (Figure 4.1A). In contrast, in aged macrophages, five miRs 
were similarly dysregulated in response to both acLDL and oxLDL, three downregulated and 
two upregulated (Figure 4.1B). These findings suggest that in macrophages, miRs are altered 
after exposure to cholesterol and may indeed orchestrate the macrophage’s response to 
cholesterol. Furthermore, these findings suggest that the distinct miR responses in aged versus 
young macrophages may underlie their distinct responses to exogenous cholesterol. 
We hypothesized that in addition to these cholesterol-responsive miRs, there may be a 
separate network of miRs that regulate the broad spectrum of differences between disease-
promoting, aged macrophages and young macrophages. Such miRs must not only demonstrate 




cholesterol. Five miRs were upregulated in aged macrophages and maintained the same pattern 
of dysregulation in aged versus young macrophages after treatment with acLDL or oxLDL 
(Figure 4.1C). MiR-150 was the strongest candidate for further study given that it had the 
highest fold change in aged versus young macrophages and since the others did not validate after 
further characterization. 
 
miR-150 is upregulated in aged macrophages of diverse origins 
 To validate the microarray data, we performed quantitative real-time PCR (qPCR) with 
independent samples. Indeed, aged peritoneal macrophages (PMs) had nine-fold increased miR-
150 expression at baseline compared to young PMs (Figure 4.1D). To determine whether this 
phenomenon was lineage-specific, we also measured miR-150 expression in splenic 
macrophages (SMs) and bone marrow-derived macrophages (BMDMs). Similar to PMs, we 
found that aged SMs (Figure 4.1E) and BMDMs (Figure 4.1F) exhibited three-fold higher 
expression of miR-150 at baseline compared to young SMs and BMDMs. Next, we sought to 
confirm that miR-150 upregulation in aged macrophages is unaffected by exposure to exogenous 
cholesterol or lipopolysaccharide (LPS). Indeed, aged PMs treated with acLDL, oxLDL, or LPS 
exhibited higher miR-150 expression than similarly treated young PMs (Figure 4.1G). Likewise, 
oxLDL- and LPS-treated aged BMDMs also had higher miR-150 expression compared to 
similarly treated young BMDMs (Figure 4.1H). Cumulatively, these findings provide strong 
evidence that miR-150 upregulation may indeed skew macrophages towards the disease-






miR-150 overexpression reprograms the macrophage transcriptome 
We next sought to determine the mechanism by which miR-150 skews macrophages 
towards the aged phenotype. To elucidate the cellular processes and pathways regulated by miR-
150, we performed RNA-Sequencing (RNA-Seq) to identify the transcriptomic networks 
dysregulated under conditions of miR-150 overexpression, comparing young macrophages 
transfected with miR-150 mimic (miR-150OE) to young macrophages transfected with a non-
targeting negative control mimic (NC). From RNA-Seq, we obtained an average of 35,607,314 
reads per sample (N = 11), and of these, an average of 32,535,035 reads (91.4%) mapped to the 
mouse genome (Mus_musculus reference build Ensembl_R76). We performed hierarchical 
clustering, revealing clear differences between the transcriptomes of miR-150OE and NC-
transfected peritoneal macrophages (Figure 4.2A). 
To determine the subset of these miR-150-regulated genes that are also dysregulated in 
aged macrophages, we overlaid the RNA-Seq results onto the results of a previous microarray 
we performed comparing aged versus young macrophages (see Chapter 3). The intersection 
between these gene lists identifies genes dysregulated in aged murine macrophages that may be 
regulated by miR-150 upregulation. We identified 160 commonly dysregulated genes with a |fold 
change| > 1.2 both in miR-150OE versus NC-transfected macrophages and in aged versus young 
macrophages. To determine whether these genes suggested abnormalities in specific pathways, 
which may provide insight into the mechanism by which miR-150 upregulation promotes age-
associated disease, we performed pathway analysis with MetaCore for enrichment by gene 
ontology (GO) processes, process networks, and pathway maps (Figures 4.2B, 4.2C, and 4.2D). 
Numerous diverse GO processes were enriched for, indicating that miR-150 regulates broad 




response process networks were five of the nine most enriched process networks (Figure 4.2C). 
These findings confirm that there is immune dysregulation in aged macrophages associated with 
miR-150 upregulation. Remarkably, aberrant lipid trafficking and metabolism in AMD was the 
third most enriched pathway map (Figure 4.2D), validating our hypothesis that miR-150 
regulates the transition of macrophages to the AMD-promoting phenotype.  
 
Disease-promoting macrophages have altered phospholipid and ceramide profiles 
 In AMD, the interaction between dysregulated macrophage cholesterol homeostasis and 
aging is implicated in the pathophysiology of disease. To better understand this relationship, we 
performed lipidomics to determine whether aged macrophages have altered lipid profiles as 
possible consequences of aberrant lipid trafficking and metabolism. We focused on components 
of the plasma membrane, including ceramides and phospholipids, since the composition and 
organization of the plasma membrane have been shown to regulate macrophage function (Wei et 
al., 2016). Aged macrophages contained significantly more long-chain Cer(16:0) than young 
macrophages but similar levels of very long-chain Cer(22:0) and Cer(24:0) (Figure 4.3A). 
Consistent with increased Cer(16:0), we observed a significant decrease in both the 
Cer(22:0)/Cer(16:0) and Cer(24:0)/Cer(16:0) ratios in aged versus young macrophages (Figure 
4.3B). These findings indicate that aged macrophages exhibit remodeling of their ceramide 
composition from very long-chain to long-chain species. 
In the phosphatidylglycerol (PG) class, PG-D16:0-18:1 was the only detectable species, 
and there was no significant difference in content between aged and young macrophages (Figure 
4.3C). However, numerous individual species were detected for each of the other phospholipid 




and more total phosphatidylethanolamine (PE; Figure 4.3E) than young macrophages but similar 
total phosphatidylinositol (PI; Figure 4.3F) and similar total phosphatidylserine (PS; Figure 
4.3G). Further analysis of the individual species within each phospholipid class by 2-way, 
repeated-measures ANOVA revealed a significant interaction between the main effects of 
species identity and age for all four phospholipid classes (Figures 4.3H, 4.3I, 4.3J, and 4.3K), 
indicating that the increased total PC and total PE in aged macrophages were driven by increases 
in specific species within these phospholipid classes. Post-hoc testing showed that the 
significantly increased species were generally phospholipids containing fatty acids with multiple 
double bonds, suggesting a shift toward unsaturated fatty acids (Figures 4.3H, 4.3I, 4.3J, and 
4.3K). Based on these findings, we propose that aberrant lipid trafficking and cholesterol 
metabolism in aged macrophages leads to this disruption in ceramide and phospholipid profiles, 
which may contribute to macrophage dysfunction in age-associated diseases. 
 
miR-150 upregulation is associated with age-related macular degeneration in humans 
 To assess the translational relevance of these findings, we recruited human patients with 
early AMD or advanced neovascular (wet) AMD and non-AMD controls in a case-control study 
design. Demographic and clinical information of the participants are shown in Table 4.1. From 
these patients, we collected peripheral blood mononuclear cells (PBMCs), which contain 
monocytes, and quantified miR-150 copy number in these samples. On average, AMD patients 
had significantly higher PBMC miR-150 levels compared to control subjects (Figure 4.4A). 
When we subdivided AMD patients into early AMD and wet AMD groups, we observed higher 
PBMC miR-150 levels in early AMD patients compared to controls and in wet AMD patients 




miR-150 levels between early and wet AMD patients (Figure 4.4B). These findings suggest that 
increased PBMC miR-150 levels are associated with developing AMD but not with disease 
progression. We next sought to determine whether age affected PBMC miR-150 levels since 
AMD patients tended to be older than non-AMD controls (Table 4.1). We found that there was 
no significant correlation between age and PBMC miR-150 levels in AMD patients (rs = 0.1596, 
P = 0.3066) or in control subjects (rs = -0.2002, P = 0.1157) (Figure 4.4C), suggesting there is 
no significant association between PBMC miR-150 levels and age. 
To model the relationship between PBMC miR-150 levels and AMD status and to 
rigorously control for a possible – albeit unlikely – effect of age, we generated a binary logistic 
regression model with the predictor variables of age, gender, and log10-transformed PBMC miR-
150 levels and the outcome of AMD. The overall model was statistically significant (LR Χ2 = 
47.4, df = 3, P < 0.001) and had good fit (Χ2 = 9.4, df = 8, P = 0.311). As expected, age was a 
significant predictor of AMD (P < 0.001) with a beta coefficient of 0.082, indicating that each 
additional year of age was associated with increased odds of having AMD (aOR = 1.086; 95% 
CI = 1.04 to 1.13). Of significant interest, even after controlling for the effects of age and gender 
on miR-150 levels, log10-transformed PBMC miR-150 levels were highly associated with AMD 
(P < 0.001) with a beta coefficient of 3.367, indicating that each additional 10-fold increase in 
PBMC miR-150 levels was associated with a 29.0-fold increased odds of having AMD (95% CI 
= 5.9 to 141.5). To determine the efficacy of PBMC miR-150 levels as a potential marker of 
AMD, we generated a receiver operating characteristic (ROC) curve and found that the area 





Furthermore, we performed conjunctive analysis to illustrate the relationship between 
PBMC miR-150 levels, age, and the outcome of AMD. We divided patients into tertiles by 
PBMC miR-150 levels (cutoffs of 4.5×106 and 9.5×106 copies/ng RNA) and by age (i.e., above 
versus below median of 67.47 years), tabulating the AMD prevalence in each conjoined cell 
(Table 4.2). This analysis demonstrated a clear stepwise increase in prevalence of AMD going 
from the lowest to the highest tertile of PBMC miR-150 levels in participants both above median 
age (i.e., from 18.8% to 53.8% to 87.5%) and below median age (i.e., from 15.8% to 17.4% to 
45.5%). These findings strongly support the notion that increased PBMC miR-150 levels are 
associated with AMD. This trend held true both above and below median age, making it highly 
unlikely that the differences in PBMC miR-150 levels in AMD patients versus non-AMD 
controls were solely due to the fact that the AMD patients were, on average, older in age.  
 
miR-150 directly targets stearoyl-CoA desaturase-2 and promotes pathologic angiogenesis 
To understand the mechanism by which miR-150 promotes macrophage dysfunction, we 
sought to identify direct miR-150 targets. Since miRs canonically downregulate their gene 
targets, we filtered for commonly downregulated genes (fold change < -1.2) both in miR-150OE 
and NC-transfected macrophages and in aged versus young macrophages. This strategy 
identified 36 initial putative target genes (Table 4.3). We further narrowed this list by 
eliminating genes that either did not appear in any of six target identification databases or did not 
contain a seed sequence in their 3′ UTR. We performed qPCR in aged versus young 
macrophages on the remaining 26 genes. Of these 26 genes, eight showed significant 
downregulation in aged macrophages (Figures 4.5A and 4.5B). Of interest, two of the eight 




fatty acid biosynthesis: fatty acid synthase (Fasn) and stearoyl-CoA desaturase-2 (Scd2). We 
confirmed that both genes were indeed downregulated in miR-150OE macrophages versus NC-
transfected macrophages (Figures 4.5C and 4.5D). To determine the functional effect of Fasn 
and Scd2 deficiency, we performed siRNA knockdown of these gene targets in macrophages and 
assessed the inflammation status and angiogenic potential of these macrophages by PCR array. 
We confirmed siRNA knockdown of Fasn and Scd2 by qPCR (Figures 4.5E and 4.5F). Fasn-
deficient macrophages exhibited upregulation of only Ptgs2 and Tnf (Figure 4.5G) and no 
upregulation of proangiogenic factors (Figure 4.5H). On the other hand, Scd2-deficient 
macrophages were abnormally activated with upregulation of numerous proinflammatory 
markers (Figure 4.5I) and proangiogenic factors (Figure 4.5J). Of interest, Vegfa expression 
was not altered (Figure 4.5J), suggesting that Scd2-mediated regulation of macrophage function 
is independent from vascular endothelial growth factor (VEGF). These results suggest that Scd2 
may be an important direct target of miR-150, providing a mechanism by which miR-150 
regulates macrophage function. 
Next, we performed dual-reporter assays to confirm that miR-150 can directly regulate 
Scd2 expression. The Scd2 gene contains two canonical miR-150 seed sequence target sites in its 
3′ UTR: a 7mer-A1 (UGGGAGA) and an offset 6mer (UUGGGA) (Figure 4.6A). As expected, 
co-transfection of a plasmid with the Scd2 3′ UTR cloned downstream of a secreted Gaussia 
luciferase (GLuc) and miR-150 mimic led to decreased GLuc activity compared to co-
transfection of the same plasmid with a non-targeting mimic (Figure 4.6B). Removing the 7mer-
A1 target site (mutant1) significantly reduced the extent to which miR-150 co-transfection 
reduced GLuc activity (Figure 4.6C). In contrast, removing the offset 6mer target site (mutant2) 




(Figure 4.6C). These findings suggest that the 7mer-A1 site is the dominant target site to which 
miR-150 binds to regulate Scd2 expression, while the offset 6mer site plays a less important role. 
To determine whether downregulation of Scd2 may promote pathological angiogenesis as 
seen in wet AMD, we measured the extent to which Scd2-deficient macrophages inhibited 
choroidal neovascularization (CNV) in a well-established murine model of injury-induced 
angiogenesis in the eye. Although host macrophages play an important role in regulating CNV, 
we have previously demonstrated that intravitreal injection of functional macrophages can 
augment the anti-angiogenic effect (Apte et al., 2006). Therefore, we performed laser injury to 
induce CNV and injected Scd2-deficient or NC-transfected macrophages intravitreally by 
adoptive transfer immediately after injury. Adoptively transferred Scd2-deficient macrophages 
were not able to inhibit choroidal neovascularization as effectively as NC-transfected 
macrophages (Figures 4.6D and 4.6E). This phenomenon was independent of VEGF since 
VEGF mRNA expression and protein secretion was not increased in Scd2-deficient macrophages 
(Figures 4.5H and 4.6F). To confirm these in vivo results, we also generated mice lacking Scd2 
in myelomonocytic cells, including macrophages, with the Cre-lox system (Scd2-m/-m). In 
agreement with our adoptive transfer experiments, Scd2-m/-m mice had larger CNV complexes 
after laser injury compared to floxed controls (Scd2f/f) (Figures 4.6G and 4.6H). In contrast, 
mice lacking Fasn in myelomonocytic cells (Fasn-m/-m) and floxed controls (Fasnf/f) had similar 
CNV complex sizes after laser injury (Figures 4.6I and 4.6J). These findings confirm that Scd2 
plays an important role in regulating macrophage function in the context of pathological 
angiogenesis. 
Together, these findings indicate that Scd2 downregulation secondary to miR-150 




angiogenesis, providing a mechanism by which miR-150 can direct macrophages towards an 
aged, disease-promoting, and proangiogenic phenotype (Figure 4.7). Our human data confirm 
the translational relevance of these findings in AMD pathogenesis. 
 
4.4 Discussion 
In this study, we report that miR-150 is upregulated in aged murine macrophages of 
diverse origins and directs aged macrophages towards a disease-promoting phenotype 
characterized by abnormal activation and promotion of pathologic angiogenesis. miR-150 was 
previously reported to play important roles in controlling B-cell differentiation by targeting the 
transcription factor c-Myb (Xiao et al., 2007). Moreover, miR-150 has been reported to regulate 
de novo lipogenesis by targeting Fasn and other lipid-related genes in mammary epithelium 
(Heinz et al., 2016). Here, we uncover a novel role for miR-150 in macrophages to regulate 
cholesterol metabolism and lipid trafficking genes involved in AMD based on our RNA-Seq 
results. In agreement, other miRs have been shown to regulate cholesterol homeostasis. For 
example, miR-33 (Rayner et al., 2011; Sene et al., 2013), miR-302a (Meiler et al., 2015), and 
miR-19b (Lv et al., 2014) regulate reverse cholesterol transport by modulating Abca1 expression. 
Consistent with their impaired cholesterol metabolism and lipid trafficking, we report that 
aged macrophages with miR-150 upregulation have associated alterations in ceramide and 
phospholipid profiles. These results build on our previous finding that aged macrophages have 
impaired cholesterol efflux (Sene et al., 2013). Specifically, aged macrophages have a reduced 
ratio of very long-chain to long-chain ceramides. Ceramides are important signaling molecules in 
macrophages that modulate cellular responses in many pathways, including inflammation 




significantly associated with mortality in coronary artery disease patients independently of 
traditional risk factors (Tarasov et al., 2014), highlighting their importance in disease 
pathogenesis. Additionally, we demonstrate that aged macrophages have alterations in 
phospholipid composition in multiple classes. Of interest, both ceramides and phospholipids are 
important components of the plasma membrane, and the composition and organization of the 
plasma membrane have been shown to be important for modulating cholesterol-dependent 
signaling networks involved in inflammation (Wei et al., 2016). 
We propose that broad disruptions in plasma membrane lipids secondary to miR-150 
upregulation in aged macrophages modulate the inflammatory status of aged macrophages and 
thereby predispose them toward a disease-promoting, proangiogenic phenotype. Our lipidomic 
analysis shows that aged macrophages possess a complex profile of altered lipid composition 
with remodeling toward long-chain ceramides and a shift towards phospholipids containing 
unsaturated fatty acids. We provide further insight by demonstrating that one molecular 
mechanism by which miR-150 regulates lipid metabolism in macrophages is by directly targeting 
Scd2. This gene catalyzes the rate-limiting step in the formation of monounsaturated fatty acids 
and has been shown to be important in lipid synthesis during early skin and liver development 
(Miyazaki et al., 2005). Our data establish that Scd2 is also evidently important in macrophage 
function, as Scd2-deficient macrophages exhibit abnormal activation and promote pathological 
angiogenesis. Although Scd2 deficiency alone might be expected to cause accumulation of 
phospholipids containing saturated fatty acids in aged macrophages, we did not observe this 
pattern in our lipidomic analysis, suggesting that Scd2 deficiency does not drive alterations in 
lipid composition alone. We propose instead that the combination of Scd2 deficiency and 




Of translational relevance, our study provides strong evidence that miR-150 plays a role 
in AMD pathogenesis. Specifically, our data indicate not only that AMD patients have higher 
PBMC miR-150 levels than control participants but also that increased PBMC miR-150 is 
significantly associated with increased odds of AMD in a gender- and age-adjusted binary 
logistic regression model. Although miR-150 levels were associated with disease in human 
PBMCs, there was no clear relationship between miR-150 levels and age, unlike in murine 
macrophages, highlighting a difference between murine and human macrophages. 
Overall, our findings are timely given a recent report that showed that there is an increase 
in the number of choroidal macrophages in human eyes with AMD (McLeod et al., 2016), 
strongly implicating a pathogenic role for macrophages in disease. Moreover, our findings may 
partially explain why activated macrophages derived from neovascular AMD patients have 
proangiogenic characteristics (Hagbi-Levi et al., 2017; Nakamura et al., 2015). While other 
groups have suggested endothelial miR-150 may suppress pathologic ocular neovascularization 
(Liu et al., 2015; Shen et al., 2008), our findings highlight a distinct, macrophage-specific role 
for miR-150 that, in fact, promotes pathological ocular neovascularization. These differences are 
not surprising given that miRs can act in a cell-specific manner. Ultimately, these findings open 
up novel therapeutic vistas for miR-based therapies for AMD. Moreover, understanding the 
mechanisms that cause macrophage aging and how aging contributes to AMD also has broad 
applicability to other age-associated diseases by educating us about critical unifying pathways 







Animals. We obtained 18-month-old, wild-type C57BL/6J mice from the National Institute on 
Aging (Bethesda, MD) and compared them to strain-matched, young (i.e., 2- to 3-month-old) 
wild-type controls. We obtained mice with floxed Fasn alleles (Fasnf/f) (Chakravarthy et al., 
2005) from Clay Semenkovich (Washington University School of Medicine, St. Louis, MO) and 
mice with floxed Scd2 alleles (Scd2f/f) (Lai et al., 2017; Masuda et al., 2015) from Hide 
Tsukamoto (Keck School of Medicine of the University of Southern California, Los Angeles, 
CA). We crossed these floxed mice with mice carrying the lysozyme M-Cre (LysMcre) 
transgene (Clausen et al., 1999) to generate mice with myelomonocytic-specific deletion of Fasn 
(Fasn-m/-m) and Scd2 (Scd2-m/-m). We harvested PMs, SMs, and BMDMs from female mice at the 
ages indicated and used equal proportions of male and female mice for laser-injury CNV 
experiments. Unless otherwise specified, we used mice that were 2-3 months of age for 
experimentation. 
 
Macrophages. We harvested PMs from mice five days after elicitation with 4% thioglycollate 
(Sigma, St. Louis, MO). We harvested SMs from mice by mincing spleens with a sharp razor 
blade, incubating in spleen dissociation medium (Stem Cell Technologies, Vancouver, Canada) 
for 30 minutes at room temperature and performing magnetic cell separation with the PE 
selection kit (Stem Cell Technologies) and PE-conjugated F4/80 monoclonal antibody (clone: 
BM8; eBioscience, Waltham, MA), following manufacturer’s instructions. We cultured PMs and 
SMs in RPMI 1640 medium (Thermo Fisher, Waltham, MA) supplemented with 10% fetal 
bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA) and 1% penicillin-streptomycin 




culturing bone marrow aspirates from mice in RPMI 1640 medium (Thermo Fisher) 
supplemented with 20% L929-conditioned medium, 10% FBS (Atlanta Biologicals), 1% 
GlutaMAX (Thermo Fisher), and 1% penicillin-streptomycin (Thermo Fisher). Monocytes were 
allowed to differentiate for one week prior to experimentation. When indicated, we treated 
macrophages with 25 µg/ml oxidized LDL (oxLDL; Intracel, Frederick, MD) for 24 hours, 25 
µg/ml acetylated LDL (acLDL; Intracel, Frederick, MD) for 24 hours, or 100 ng/ml 
lipopolysaccharide (LPS; Sigma, St. Louis, MO) for 24 hours. 
 
MicroRNA microarray. We profiled microRNA (miR) expression of young and aged peritoneal 
macrophages that 1) were left untreated, 2) treated with 25 µg/ml acLDL for 24 hours, or 3) 
treated with 25 µg/ml oxLDL for 24 hours (total of 6 groups; 3 treatments × 2 ages). We 
extracted RNA with the mirVana miRNA isolation kit (Thermo Fisher), determining quantity 
and quality of the RNA with a 2100 BioAnalyzer and the Total RNA Pico kit (Agilent 
Technologies, Santa Clara, CA). All samples (N = 24) had RNA Integrity Numbers > 9.5. We 
labeled each sample with FlashTagTM Biotin HSR RNA Labeling Kits (Affymetrix, Santa Clara, 
CA) to prepare them for the GeneChip® miRNA 3.0 Array. We processed the array results with 
Affymetrix Expression Console (v1.3.1.187) at standard settings (RMA background correction, 
median polish summarization, and quantile normalization) to generate intensity values with a 
second set of data produced without quantile normalization. We filtered the data by probeset type 
and by detection call and removed probesets without a ‘detected’ call in any of the 24 samples; 
after this filtering, we retained 1,093 of the initial 1,966 probesets for further statistical analysis. 
To identify potential outliers, we performed principal component analysis (PCA) and 




all probeset RLE means > 0.25). This analysis identified 3 outliers, which we omitted from 
further analysis. We performed statistical analysis with the R package “limma” (Ritchie et al., 
2015) to generate lists of miRs differentially expressed in our various groups based on their p-
values and false detection rate (FDR)-adjusted p-values (i.e., q-values). The microarray data are 
available at the Gene Expression Omnibus (GEO) at NCBI under accession number GSE111323. 
 
microRNA expression profiling. For miR expression profiling, we extracted total RNA with the 
mirVana miRNA isolation kit (Thermo Fisher) and prepared cDNA with the universal cDNA 
synthesis kit II (Exiqon, Woburn, MA). We then performed qPCR using ExiLENT SYBR® 
Green master mix (Exiqon) and microRNA LNATM primer sets (Exiqon). To analyze the data, 
we used the ΔΔCT method, normalizing to U6 expression. 
 
mRNA expression profiling. For mRNA expression profiling, we extracted RNA with the 
RNeasy kit (Qiagen, Germantown, MD) and prepared cDNA with the high-capacity cDNA 
reverse transcription kit (Thermo Fisher). We then performed qPCR with TaqManTM fast 
advanced master mix (Thermo Fisher) and TaqManTM real-time PCR gene expression assays 
(Thermo Fisher). We also profiled mRNA expression with custom TaqManTM array plates 
(Thermo Fisher). We used the ΔΔCT method, normalizing to one or more housekeeping gene(s), 
as appropriate. 
 
RNA-Sequencing. We extracted total RNA from peritoneal macrophages transfected with either 
synthetic mir-150-5p or negative control (Exiqon) with TRIzol (Thermo Fisher) followed by 




quality of the RNA samples with a 2100 BioAnalyzer and the Total RNA Pico kit (Agilent 
Technologies). All samples (N = 12) had RNA Integrity Numbers > 9.6. We analyzed the 
transcriptomes of peritoneal macrophages after miR-150 overexpression with RNA-Sequencing 
(RNA-Seq) with an initial input of 600 ng of total RNA per sample before mRNA enrichment 
with the rRNA Ribo-Zero rRNA removal kit (Illumina, San Diego, CA). We prepared 
sequencing libraries with standard protocols. Quality control revealed improper fragmentation of 
one sample, which was omitted from further analysis. The remaining samples (N = 11) were 
sequenced in two flowcell lanes on a HiSeq 2500 (Illumina) at the Washington University 
GTAC. We mapped the sequencing reads to the genome with STAR. Next, we performed a 
standard EdgeR and Sailfish analysis of gene-level features. We defined a significant up- or 
down-regulation as a |fold-change| > 1.20 with a false-detection rate (FDR) < 0.20. We 
performed pathway analysis for enrichment in gene ontology (GO) processes, process networks, 
and pathway maps with MetaCore (Clarivate Analytics, Philadelphia, PA). The RNA-Seq data 
are available at the Gene Expression Omnibus (GEO) at NCBI under accession number 
GSE111323. 
 
Lipidomic analysis. We suspended macrophages in PBS at 2.0×106 cells/ml and performed 
protein precipitation from 100 µl of macrophage suspension to extract ceramides, 
phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, phosphatidylglycerols, 
and phosphatidylserines. Prior to extraction, we added deuterated d5-Cer (16:0), d4-Cer (22:0), 
and d4-Cer (24:0) as internal standards for ceramides and PC (28:2), PE (32:2), PG (30:0), PI 
(32:0) and PS (28:0) as internal standards for the other lipid classes. We measured lipids with a 




(Kyoto, Japan) coupled to a Thermo Scientific TSQ Quantum Ultra triple quadrupole mass 
spectrometer operated in SRM mode under ESI(+). We conducted data processing with 
XcaliburTM (Thermo Fisher). We prepared quality control (QC) samples by pooling aliquots of 
the study samples and injected them between every five samples to monitor instrument 
performance, omitting lipid species with coefficients of variance >15% in QC samples. We 
performed relative quantification by comparing the peak area ratios of the analytes to the 
corresponding internal standards. 
 
Human subjects. To isolate peripheral blood mononuclear cells (PBMCs), we performed 
density gradient centrifugation with BD Vacutainer CPTTM cell preparation tubes (Franklin 
Lakes, NJ). We stored PBMC pellets at -80°C until further analysis. We classified patients as no 
AMD, early AMD, or wet AMD based on established clinical criteria (Ferris et al., 2005). Early 
AMD patients had either moderate drusen (>63 µm) or pigment changes in at least one eye but 
no CNV or GA in either eye at the time of sample collection. Wet AMD patients had CNV in at 
least one eye at the time of sample collection. We excluded patients with pattern dystrophy, 
macular telangiectasia, dominant drusen, or central serous chorioretinopathy. 
 
Absolute microRNA-150 quantification in human PBMCs. We extracted RNA from PBMCs 
with the mirVanaTM miRNA isolation kit (Thermo Fisher) and performed reverse transcription 
(RT) with the universal cDNA synthesis kit II (Exiqon) by adding 2 µl of RNA to 2 µl of 5× 
reaction buffer, 1 µl of enzyme mix, and 5 µl of nuclease-free H2O (total volume: 10 µl). We 
diluted the cDNA to a final volume of 60 µl and performed miRCURY LNA Universal RT 




ExiLENT SYBR Green master mix (total volume: 10 µl). To determine absolute copy number of 
hsa-miR-150-5p, we prepared standard curves with serial dilutions of synthetic hsa-miR-150-5p 
(Integrated DNA Technologies, Coralville, IA) ranging from 104 copies per 2 µl input to 1010 
copies per 2 µl input, followed by RT and PCR as above. To account for differences in RNA 
extraction and RT efficiency performed on separate occasions, we spiked in 20 fmol of synthetic 
cel-miR-39-3p (Integrated DNA Technologies) into each sample prior to RNA extraction and 
normalized to the global arithmetic mean. We normalized miR-150 copy number for each patient 
by dividing by the total RNA used for RT. 
 
miR-150 overexpression. To transiently overexpress miR-150 in peritoneal macrophages, we 
used commercially available miRCURY LNATM microRNA mimics (Exiqon), following 
standard protocols for fast-forward transfection. In short, we plated peritoneal macrophages at 
1.0×106 cells/well in 6-well plates. Two hours after plating, we prepared transfection complexes 
by combining miR mimic (20 nM) and HiPerFect transfection reagent (18 µl/well; Qiagen) in 
RPMI medium supplemented with 10% FBS (Atlanta Biologicals) and 1% penicillin-
streptomycin (Thermo Fisher), incubating for 15 minutes at room temperature before adding to 
the cells. We assessed transfection efficiency with fluorescence microscopy by visualizing FAM-
labeled microRNA mimics. 
 
miR-150 target identification. To identify miR-150 targets, we retrieved 3′ UTR sequences 
from the UCSC Genome Brower (genome.ucsc.edu; Mouse Assembly GRCm38/mm10) and 
manually searched for the presence of relevant miR-150 seed sequences (8mer site: 




offset 6mer site: UUGGGA). Additionally, we used existing miR target identification databases: 
TargetScanMouse (Release 7.1) (Agarwal et al., 2015), DIANA-microT-CDS (Version 5.0) 
(Paraskevopoulou et al., 2013), DIANA-TarBase (Version 7.0) (Vlachos et al., 2015), miRDB 
(Wong and Wang, 2015), RNA22 (Version 2.0) (Miranda et al., 2006), and microRNA.org 
(August 2010 Release) (Betel et al., 2008). 
 
Fasn/Scd2 knockdown. To transiently knock down Fasn and Scd2, we used commercially 
available FlexiTube siRNA (Qiagen), following standard protocols for fast-forward transfection. 
In short, we plated peritoneal macrophages at 1.0×106 cells/well in 6-well plates. Two hours after 
plating, we prepared siRNA transfection complexes by combining siRNA (50 nM) and 
HiPerFect transfection reagent (18 µl/well; Qiagen) in RPMI medium supplemented with 10% 
FBS (Atlanta Biologicals) and 1% penicillin-streptomycin (Thermo Fisher), incubating for 15 
minutes at room temperature before adding to the cells. We confirmed efficient siRNA 
knockdown by qPCR. We analyzed macrophage activation and function 48 hours after 
transfection. 
 
miRNA target dual-reporter assays. We ordered custom miTargetTM 3′ UTR miRNA target 
clones from GeneCopoeia (Rockville, MD) with wild-type or mutated Scd2 3′ UTR inserted 
downstream of a secreted Gaussia luciferase (GLuc) reporter gene driven by the SV40 promoter 
and a secreted alkaline phosphatase (SEAP) reporter gene driven by a CMV promoter. We co-
transfected 293T cells (ATCC, Manassas, VA), cultured routinely in high-glucose DMEM 
(Thermo Fisher) supplemented with 10% FBS (Atlanta Biologicals), with the target clone and 




manufacturer’s instructions. In brief, we plated 293T cells in 96-well plates at 2.0×104 cells/well 
the day before transfection. On the day of transfection, we prepared transfection complexes by 
combining the target clone (100 ng/well), miR mimic (20 nM), LipofectamineTM 3000 (0.15 
µl/well; Thermo Fisher), and P3000TM reagent (0.20 µl/well) in Opti-MEMTM medium (Thermo 
Fisher) and incubating for 30 minutes at room temperature before adding to the cells. 48 hours 
after transfection, we collected the supernatant to measure GLuc activity with the Secrete PairTM 
Dual Luminescence assay kit (GeneCopoeia). We normalized for transfection efficiency by 
measuring SEAP activity. We optimized co-transfection conditions with a positive-control 
pmaxGFPTM plasmid (Lonza, Basel, Switzerland). 
 
Choroidal neovascularization (CNV) experiments. We performed laser-induced choroidal 
neovascularization as described previously (Dong et al., 2013). Briefly, we anesthetized mice 
and placed four laser spots around the optic disc (200 mW, 0.1 s, 100 µm spot size) using a slit-
lamp delivery system with a cover glass as a contact lens. Seven days after injury, we perfused 
the mice with 2,000 µl of 5 mg/ml fluorescein isothiocyanate (FITC)-dextran (M.W. 2,000,000; 
Sigma) through the left ventricle. We then enucleated the eyes and fixed them in 2% 
paraformaldehyde (PFA; Alfa Aesar, Haverhill, MA) for 30 minutes. After fixation, we washed 
the eyes with PBS and flat-mounted the RPE-choroid complex onto a glass slide. We acquired Z-
stack images of the CNV spots using an Olympus FV1000 confocal microscope (Waltham, MA) 
and processed images with ImageJ (NIH, Bethesda, MD) to generate pseudo-volumetric two-
dimensional images. After excluding laser spots that resulted in retinal, subretinal, or vitreous 
hemorrhage, we quantified pixel intensity using MetaMorph (Molecular Devices, Sunnyvale, 




eye in 2 µl PBS immediately following laser injury via intravitreal injection with a 10 µl Neuros 
Model 1701 RN syringe (point style 4) and small-hub, 31-gauge needles (Hamilton, Reno, NV). 
 
VEGF measurements. We measured VEGF secretion in supernatants from macrophages with 
the mouse VEGF Quantikine ELISA kit (R&D Systems, Minneapolis, MN), following 
manufacturer’s instructions. 
 
Statistics. We performed statistical analysis with Prism 5 (Graphpad) or SPSS Statistics 
(Version 23; IBM, Armonk, NY). We assessed the normality of our data graphically and with the 
Kolmogorov-Smirnov test, using non-parametric alternatives when appropriate. When 
comparing a single variable between two groups, we used 2-tailed t-tests or 2-tailed Mann-
Whitney U tests. For other analyses, we performed the appropriate statistical test for each type of 
data. A P-value less than 0.05 was considered significant. Open circles depict individual data 
points or individual human subjects. Box-and-whisker plots depict medians with boxes outlining 
the interquartile range and whiskers indicating the minima and maxima. 
We performed an a priori power calculation with G*Power 3.1 (Faul et al., 2007) to 
determine the appropriate sample size for our human studies. To detect a significant difference 
between AMD patients and control subjects (allocation ratio: 1.0:1.5) at the two-sided α = 0.05 
level with an estimated effect size d of 0.6 based on pilot experiments and 80% power, we 
calculated that we needed to recruit 94 subjects total. We exceeded this threshold (N = 106), 
yielding adequate statistical power to detect our anticipated difference. To model the relationship 
between PBMC miR-150 levels and AMD, we generated a binary logistic regression model. Our 




transformed PBMC miR-150 levels. We assessed model fit with the Hosmer-Lemeshow lack-of-
fit test and performed model diagnostics by examining Cook’s distances, leverages, and residual 
deviances. No cases were omitted upon sensitivity analysis. We checked for collinearity by 
examining variance inflation factors (VIF). We used an unadjusted alpha of 0.05 for the binary 
logistic regression. 
 
Study approval. All animal experiments were reviewed and approved by the Institutional 
Animal Care and Use Committee (IACUC) of Washington University in St. Louis (St. Louis, 
MO) and performed in accordance with the Washington University School of Medicine Animal 
Care and Use guidelines. The human study was reviewed and approved by the Human Research 
Protection Office of Washington University in St. Louis (St. Louis, MO) and adhered to the 
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Figure 4.1. microRNA-150 is upregulated in aged macrophages of diverse origins. (A) In young macrophages, ten 
microRNAs were downregulated similarly in response to acetylated low-density lipoprotein (acLDL) and oxidized 
low-density lipoprotein (oxLDL). (B) In aged macrophages, five microRNAs were dysregulated similarly in 
response to acLDL and oxLDL. (C) In untreated (UT), acLDL-treated, and oxLDL-treated macrophages, five 
microRNAs were dysregulated similarly in aged and young macrophages under the same treatment conditions. 
microRNA-150 was upregulated in aged peritoneal macrophages (PM) (D; N=12/group; 2-tailed Mann-Whitney U 
test), aged splenic macrophages (SM) (E; N=13/group; 2-tailed Mann-Whitney U test), and aged bone marrow-
derived macrophages (BMDM) (F; N=10/group; 2-tailed, unpaired Welch’s t-test). (G) Upregulation of microRNA-
150 in aged PMs was not affected by treatment with acLDL (N=7/group; 2-tailed Mann-Whitney U test), oxLDL 
(N=7/group; 2-tailed, unpaired Welch’s t-test), or lipopolysaccharide (LPS) (N=5/group; 2-tailed Mann-Whitney U 
test). (H) Upregulation of microRNA-150 in aged BMDMs was not affected by treatment with oxLDL (N=5/group; 
2-tailed Mann-Whitney U test) or LPS (N=5/group; 2-tailed Mann-Whitney U test). Open circles depict individual 





Figure 4.2. microRNA-150 (miR-150) regulates inflammation and lipid metabolism in macrophages. (A) RNA-
Sequencing followed by hierarchical clustering revealed clear transcriptomic differences between macrophages 
transfected with miR-150 mimic versus those transfected with a non-targeting negative control. Pathway analysis of 
the dysregulated genes in miR-150-overexpressing macrophages that are also dysregulated in aged macrophages 
(Lin et al., unpublished observations) suggested perturbations in numerous gene ontology (GO) processes (B), 
process networks (C), and pathway maps (D). The altered transcriptomic profile of miR-150-overexpressing 
macrophages suggested dysregulation of numerous inflammation and immune response process networks (C; brown 








Figure 4.3. Aged macrophages have altered ceramide and phospholipid profiles. (A) Aged macrophages contained 
significantly more long-chain Cer(16:0) than young macrophages but similar levels of very long-chain Cer(22:0) 
and Cer(24:0) (N=5/group; 2-tailed, unpaired Welch’s t-test), resulting in decreased Cer(22:0)/Cer(16:0) and 
Cer(24:0)/Cer(16:0) ratios (B; N=5/group; 2-tailed, unpaired Welch’s t-test). Young and aged macrophages had 
similar phosphatidylglycerol (PG)-D16:0-18:1 content (C; N=5/group; 2-tailed, unpaired student’s t-test). Aged 
macrophages had higher total phosphatidylcholine (PC) (D; N=5/group; 2-tailed, unpaired student’s t-test) and 
higher total phosphatidylethanolamine (PE) (E; N=5/group; 2-tailed, unpaired student’s t-test) but similar total 
phosphatidylinositol (PI) (F; N=5/group; 2-tailed, unpaired Welch’s t-test) and similar total phosphatidylserine (PS) 
(G; N=5/group; 2-tailed, unpaired Welch’s t-test). Analysis of individual species revealed an interaction between 
age and species identity with increased levels of certain species but not others within each phospholipid class (H-K; 
N=5/group; 2-way, repeated-measures ANOVA with Bonferroni post-hoc test). Open circles depict individual data 





Figure 4.4.  Upregulation of microRNA-150 in human peripheral blood mononuclear cells (PBMCs) is associated 
with age-related macular degeneration (AMD). (A) AMD patients (N=43) had higher PBMC microRNA-150 copy 
numbers compared to controls (N=63; 2-tailed Mann-Whitney U test). (B) Both early AMD (N=20) and wet AMD 
patients (N=23) had higher PBMC microRNA-150 copy numbers compared to controls (N=63), but there was no 
significant difference between early and wet AMD patients (Kruskal-Wallis test with Dunn’s multiple comparison 
post-hoc test). (C) There was no correlation between PBMC microRNA-150 copy number and age in AMD patients 
or controls. Patients in the highest tertile of microRNA-150 copy number and above median age, as indicated by the 
dashed rectangle, had the highest prevalence of AMD (87.5%). Open circles depict individual human subjects (A-







Figure 4.5. microRNA-150 modulates fatty acid synthase (Fasn) and stearoyl-CoA desaturase-2 (Scd2) expression. 
(A-B) Eight of the 26 putative microRNA-150 targets had decreased expression in aged macrophages (N=6-
12/group; 2-tailed, unpaired Welch’s t-test). (C-D) microRNA-150 mimic-transfected macrophages had reduced 
expression of Fasn and Scd2 compared to non-targeting negative control (NC)-transfected macrophages 
(N=12/group; 2-tailed, unpaired student’s t-test). (E-F) Macrophages transfected with Fasn- and Scd2-targeting 
small-interfering RNA (siRNA) had reduced expression of target genes (N=4-5/group; 2-tailed, unpaired student’s t-
test). (G-H) Fasn-deficient (FasnKD) macrophages were somewhat abnormally activated but had normal expression 
of proangiogenic factors (N=14/group; 2-tailed, unpaired Welch’s t-test). (I-J) Scd2-deficient (Scd2KD) macrophages 
were abnormally activated and had increased expression of proangiogenic factors (N=10/group; 2-tailed, unpaired 
Welch’s t-test). Open circles depict individual data points; graphs depict mean ± S.E.M. (C-F) (* P < 0.05; ** P < 







Figure 4.6. microRNA-150 directly targets Scd2 and thereby promotes pathological angiogenesis.  (A) The 3′ 
untranslated region (UTR) of Scd2 contains canonical 7mer-A1 and offset 6mer microRNA-150 binding sites. (B) 
Co-transfection of a dual-reporter plasmid with the Scd2 3′ UTR inserted downstream of a secreted Gaussia 
luciferase (GLuc) reporter gene and microRNA-150 mimic led to reduced GLuc activity compared to co-
transfection of the same plasmid with a negative-control (NC) mimic (N=10/group; 2-tailed, unpaired student’s t-
test). (C) Removing the 7mer-A1 target site (mutant1) but not the offset 6mer target site (mutant2) reduced the 
extent to which microRNA-150 co-transfection inhibited GLuc activity (N=10/group; Kruskal-Wallis test with 
Dunn’s multiple comparison post-hoc test; WT = wild-type). (D-E) Adoptively transferred Scd2-deficient (Scd2KD) 
macrophages were less able to inhibit laser injury-induced choroidal neovascularization (CNV) compared to NC-
transfected macrophages (D: representative images from N=8-11 burns/group; 2-tailed, unpaired Welch’s t-test). (F) 
In vitro VEGF secretion was not significantly increased in Scd2-deficient macrophages (N=16/group; 2-tailed, 
unpaired Welch’s t-test). (G-H) Scd2-m/-m mice exhibited larger CNV complexes after laser injury compared to 
Scd2f/f mice (G: representative images from N=8-9 burns/group; 2-tailed Mann-Whitney U test). (I-J) Fasn-m/-m and 
Fasnf/f mice had similarly sized CNV complexes after laser injury (I: representative images from N=8 burns/group; 
2-tailed Mann-Whitney U test). Scale bars represent 100 µm (D, G, I). Open circles depict individual data points; 





Figure 4.7. Upregulation of miR-150 in aged macrophages causes stearoyl-CoA desaturase-2 deficiency and 






Table 4.1. Demographic and clinical characteristics of human subjects. 
Variable Control AMD P-value 
Age, mean (standard deviation)  64.57 (10.27) 75.48 (12.77) <0.001a  
Sex, N       
     Male  36 20  0.282b  
     Female  27 23   
AMD status, N       
     No AMD  63 0  N/A 
     Early AMD  0 20   
     Advanced neovascular (wet) AMD  0 23   






Table 4.2. Age-related macular degeneration as a function of age and peripheral blood 
mononuclear cell (PBMC) microRNA-150 (miR-150) levels. 
 
    Age 









 Lowest tertile 3/19 (15.8%) 3/16 (18.8%) 6/35 (17.1%) 
Middle tertile 4/23 (17.4%) 7/13 (53.8%) 11/36 (30.6%) 
Highest tertile 5/11 (45.5%) 21/24 (87.5%) 26/35 (74.3%) 





Table 4.3. List of putative microRNA-150 targets. 
Gene symbol Fold change 
(aged versus young) 
Fold change 
(miR-150OE versus NC) 
3110070M22Rik -1.39 -1.86 
Aldoc -1.85 -1.30 
Atp1a3 -1.46 -1.25 
Ak8 -1.42 -1.25 
Cbx8 -1.28 -1.46 
Cd33 -1.48 -1.23 
Agap1 -1.33 -1.30 
S100a8 -1.21 -1.49 
Slc29a1 -1.30 -1.29 
Fasn -1.55 -1.20 
Ptgir -1.82 -1.21 
Gsn -1.26 -1.24 
Pygl -1.21 -1.21 
Insig1 -1.62 -1.26 
Itgax -1.84 -1.26 
Cers4 -1.24 -1.30 
Ldhb -1.25 -1.28 
Lpin1 -1.31 -1.21 
Mvd -1.77 -1.36 
Padi2 -1.45 -1.34 
Pik3r2 -1.20 -1.22 
Pnkd -1.51 -1.29 
Ptprs -1.34 -1.45 
Plxnd1 -1.43 -1.21 
Ptgir -1.82 -1.21 
Slc2a6 -1.51 -1.31 
Scarb1 -1.35 -1.22 
Stac2 -1.34 -1.28 
Scd2 -3.65 -1.30 
Sort1 -1.56 -1.24 
Tkt -1.25 -1.24 
Trim36 -1.61 -1.23 
F3 -1.39 -1.30 
Vsig8 -1.91 -1.29 
Wfs1 -1.36 -1.34 
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5.1 Summary: NAD+ in Retinal Degenerative Diseases  
A major cause of blindness is retinal degenerative diseases. Despite their heterogeneity, 
retinal degenerations typically converge on an endpoint of photoreceptor death, suggesting that 
they share common pathogenic mechanisms. To date, many studies of inherited retinal 
degenerations have focused on the genetic defects that cause photoreceptor death and blindness. 
Rationally, ensuing translational efforts have focused on gene therapy and stem cell approaches. 
However, these strategies have limitations since gene therapy must be tailored for each causative 
mutation, a challenging proposition since hundreds of causative gene mutations have been 
identified for blinding diseases. Moreover, stem cells do not prevent photoreceptor death and 
have many barriers to their development, such as tumorigenicity. 
The long-term goal of the first aim of my thesis research was to identify a unifying 
molecular mechanism in the pathogenesis of retinal degenerations that may lead to novel 
therapeutic approaches for preventing photoreceptor death regardless of its etiology. Since 
photoreceptors are highly metabolically active but have limited mitochondrial reserve, metabolic 
dysfunction may contribute to photoreceptor demise in diverse retinal diseases. Nicotinamide 
adenine dinucleotide (NAD+) is known to be important for metabolism both as a cofactor for 
dehydrogenases and as a cosubstrate for sirtuins that regulate mitochondrial function (e.g., 
SIRT3). The possibility that NAD+ biosynthesis is important for photoreceptor function is 
supported by recent studies identifying that Leber congenital amaurosis (LCA), one of the 
leading causes of childhood blindness, can be caused by mutations in the NAD+ biosynthetic 
enzyme, nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1). 
To complete the first aim of my thesis, I explored the role of NAD+ biosynthesis in 




phosphoribosyltransferase (Nampt), the rate-limiting enzyme in the major NAD+ biosynthetic 
pathway beginning with nicotinamide, specifically from rod or cone photoreceptors. I found that 
these mutations caused rapid retinal degeneration, which closely mirrored the clinical course of 
retinitis pigmentosa. This vision loss could be rescued with the NAD+ intermediate nicotinamide 
mononucleotide (NMN). Furthermore, I found that Nampt deletion caused NAD+ deficiency, 
which led to glycolytic dysfunction, defects in oxidative respiration, and, ultimately, 
photoreceptor death. I further demonstrated that the NAD+-dependent mitochondrial deacylases 
SIRT3 and SIRT5 play important roles in retinal homeostasis and that NAD+ deficiency also 
causes SIRT3 dysfunction, further contributing to mitochondrial dysfunction. I also identified 
that retinal NAD+ deficiency was an early feature of multiple mouse models of retinal 
dysfunction, supporting the idea that NAD+ intermediates may be therapeutic against diverse 
retinal degenerations. These therapeutic approaches would be highly innovative, as they could 
facilitate photoreceptor survival independent of the causative mutation and may also be 
therapeutic for non-inherited, blinding diseases. These findings also have broad implications for 
other neurodegenerative diseases with associated metabolic dysfunction. Although numerous 
studies have confirmed the importance of NAD+ and sirtuins in the retina and in other tissues, 
more studies are necessary to fully unleash their translational potential. 
For example, intracellular NAD+ partitions into subcellular pools in the nucleus, 
cytoplasm, and mitochondria. No study to date has determined which subcellular pool(s) of 
NAD+ are essential for photoreceptor function. The fact that mutations in NMNAT1, the 
NMNAT isoform with nuclear function, causes blindness suggests that the nuclear NAD+ pool is 
essential for vision. However, this possibility needs to be tested rigorously. Moreover, there may 




trafficking may also play pathogenic roles in disease. Further understanding of the subcellular 
organization of NAD+ is particularly important since sirtuins, molecular sensors of NAD+ 
availability, also have a distinct pattern of subcellular organization. Therefore, it is possible that 
restrictions in NAD+ availability in certain subcellular compartments but not others may cause 
impaired activity of a specific sirtuin, which are important principles to consider when 
developing novel therapeutic approaches. 
Recent studies suggest that there is also an extracellular source of NAD+, which may 
have its own important physiological role. In fact, NAMPT has two forms: intracellular NAMPT 
(iNAMPT) and extracellular NAMPT (eNAMPT). Whereas iNAMPT localizes intracellularly 
and likely contributes to NAD+ pools to be used within the cell, eNAMPT circulates in plasma 
and in other biofluids and can regulate physiology in a systemic manner. eNAMPT (also known 
as PBEF or visfatin) was previously thought to be a cytokine or a hormone based on its 
pleiotropic effects, but further investigation revealed that these effects are caused by its robust 
NAD+ biosynthetic function (Revollo et al., 2007). Recent studies have confirmed that 
eNAMPT’s ability to regulate systemic NAD+ biosynthesis allows it to regulate distant target 
cells, including pancreatic beta cells (Revollo et al., 2007) and hypothalamic neurons (Yoon et 
al., 2015). eNAMPT may also regulate retinal physiology. 
Finally, numerous studies have tested whether NAD+ intermediates are therapeutic in 
animal models of disease (Lin et al., 2016a; Mills et al., 2016; Williams et al., 2017). Human 
clinical trials have already begun to investigate whether NAD+ intermediates improve 
cardiometabolic health (NCT03151239), treat mitochondrial diseases/myopathies 
(NCT03432871), or improve cognition in patients with mild cognitive impairment 




potential of NAD+ intermediates for diverse human diseases (see clinicaltrials.gov). However, 
there still remains some uncertainly regarding the in vivo pharmacokinetics of NAD+ 
intermediates. Although both NR and NMN have been shown to boost intracellular NAD+, how 
these metabolites enter the cell remains unclear. One possibility is that there is an NMN 
transporter that allows for rapid uptake of NMN directly into the cell for intracellular conversion 
into NAD+ (Yoshino et al., 2018). However, this hypothesis was challenged by a recent study 
that demonstrated that in some, but not all, tissues, extracellular NMN must first be converted to 
NR by nicotinamide riboside kinase 1 (NRK1) before it can be transported to the intracellular 
compartment (Ratajczak et al., 2016). Further studies are essential to clarify this discrepancy. 
Future randomized clinical trials designed to evaluate safety and efficacy of NMN and NR, 
especially those that compare them head to head, will be particularly informative in clarifying 
whether one of these NAD+ intermediates has superior bioavailability. 
 
5.2 Summary: Macrophage Aging and AMD 
 We and others have previously reported that macrophages play pathogenic roles in 
diverse diseases of aging, including age-related macular degeneration (AMD), a leading cause of 
blindness in older adults, especially in industrialized countries such as the United States. Aged 
macrophages tend to drift towards a proangiogenic, M2-like phenotype, permitting pathologic 
angiogenesis. Although prior studies have explored the functional consequences of macrophage 
aging, less is known about its cellular basis or what defines the transition from physiologic aging 
to disease. The long-term goal of the second aim of my thesis research was 1) to distinguish 




that promote disease and 2) to identify one or more microRNA(s) that regulate the process of 
pathologic macrophage aging. 
I first confirmed that, despite their frequent self-renewal, macrophages from old mice 
exhibited numerous signs of aging, such as impaired oxidative respiration and increased 
expression of senescence markers. I next performed transcriptomic profiling of aged murine 
macrophages by microarray to characterize the major changes associated with macrophage 
aging. Pathway analysis revealed dysregulation of diverse cellular pathways, especially in 
cholesterol homeostasis, that manifested in altered oxysterol signatures. To assess which of these 
changes were disease-promoting, I collected human samples from human AMD patients and 
healthy controls. While certain oxysterols in human peripheral blood mononuclear cells and 
plasma exhibited age-associated changes, as in the murine samples, others such as plasma 24-
hydroxycholesterol were specifically associated with AMD after controlling for age and gender. 
These findings suggest that oxysterols can discriminate disease from physiologic aging. 
I next sought to understand the role of microRNAs, which modulate immune processes, 
in regulating macrophage dysfunction and thereby promoting age-associated diseases. I began by 
performing a microRNA microarray to identify putative candidates for microRNAs that regulate 
macrophage aging. microRNA-150 emerged as the most likely candidate, as it was upregulated 
by the highest fold change in aged macrophages of diverse origins. Next, I performed RNA-
Sequencing to assess the transcriptomic changes associated with microRNA-150 upregulation. 
Of interest, pathway analysis revealed enrichment for dysregulated genes in lipid trafficking and 
cholesterol metabolism. Molecular profiling confirmed that, consistent with impaired lipid 
homeostasis, aged murine macrophages exhibit dysregulated ceramide and phospholipid profiles 




human peripheral blood mononuclear cells was also significantly associated with increased odds 
of AMD, even after controlling for age and gender. I generated novel insights into human disease 
by showing that microRNA-150 directly targets stearoyl-CoA desaturase-2 (Scd2), which 
coordinates macrophage-mediated inflammation and pathologic angiogenesis, as seen in AMD, 
in a vascular endothelial growth factor (VEGF)-independent manner. 
Future studies will examine the molecular mechanism by which Scd2 regulates 
macrophage inflammation. These are the topics of ongoing experimentation in the Apte Lab. 
Finally, although our human data significantly strengthen the translational relevance of our 
findings, additional studies are necessary to validate our results and should incorporate and 
control for other covariates, including but not limited to known risk factors of AMD. In 
particular, the collection of longitudinal data may provide further insight into whether oxysterols 
and/or microRNA-150 may predict risk of AMD progression. These findings would be highly 
valuable to guide clinical decision-making and improve the care clinicians can offer to patients. 
 
5.3 Conclusions 
Retinal degenerative diseases are a major cause of morbidity in the modern world. Visual 
impairment significantly diminishes the quality of life of patients. A significant challenge in 
preventing blindness caused by retinal diseases is the genetic and phenotypic heterogeneity of 
the diseases and a variable understanding of disease pathogenesis. This limited understanding 
has led to either the widespread use of drugs that treat disease manifestations in relatively late 
phases of the natural history rather than the underlying cause or, in many instances, a complete 
lack of treatment options altogether. Indeed, more research is necessary to identify novel 




the pathophysiology underlying photoreceptor neurodegeneration in diverse retinal degenerative 
diseases and cellular pathways that contribute to the transition from early AMD to wet AMD. 
Ultimately, these findings may lead to new therapeutic approaches for these diverse diseases and, 
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